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ABSTRACT
Introduction of screening for prostate cancer using the prostate-specific antigen (PSA)
biomarker of the disease in the late 80ies led to remarkable dynamics of the incidence
of the disease and shortly after, cancer mortality showed a decline. Except for frag-
mentary studies, no comprehensive information exists on the PSA uptake in the
European countries that would allow specification of utilization intensity by age and
calendar time, which puts forward the problem of estimating PSA utilization pat-
terns from cancer incidence and mortality data. Even in the USA the patterns have
been heterogeneous and showed nontrivial dynamics. Capturing the picture by para-
metric methods has been very challenging. Although prostate cancer mortality rates
have fallen dramatically since the widespread adoption of PSA screening in the early
1990s, conclusively establishing screening benefit requires evidence from randomized
controlled trials. Former studies did not formally evaluate whether screening efficacy
differed between trials when implementation details such as screening patterns are
taken into account and conflicting results have been seen between trials.
In the second chapter, we formulate a joint model of cancer progression to symp-
tomatic (clinical) diagnosis and the screening process with the associated detection
mode, as both processes interact to produce the observed incidence in the population.
The risks of screening and clinical diagnosis are dependent sharing the latent tumor
onset and progression processes in the subject, denoted by a common shared frailty
term. Intensity of screening and the hazard driving prostate cancer progression are
estimated jointly and semiparametrically using the NPMLE method based on the
x
joint model. Asymptotic and finite sample properties of the proposed estimators are
studied analytically and by simulations. An application using data from the European
cancer registry EUREG is presented.
In the third chapter, we develop a semiparametric joint model of cancer progres-
sion to clinical and screening diagnosis based on screening trials data with a mixture
of known PSA test schedules per protocol and random unknown schedules before
and after implementation of the protocol in both control and screening arm. Ad-hoc
screening patterns in both arms before recruitment and after existing the trial, and
the hazard driving prostate cancer progression are estimated jointly and semipara-
metrically. Hypothesis tests comparing the screening risks between the arms and
periods are performed to validate if the randomization was contaminated. Applica-
tions using the subject-specific incidence data for both control and screening arms
from Prostate, Lung, Colorectal, and Ovarian screening trial (PLCO) and cancer inci-
dence data from The Surveillance, Epidemiology, and End Results (SEER) Program
are demonstrated.
In the fourth chapter, we derive the lead time to link cancer mortality with can-
cer incidence and screening efficacy. We use a two-step approach to formally test
whether screening efficacy differs between trials using mean lead time as a surrogate
of screening intensity. First, the mean lead time is estimated in each trial arm as a
proxy for the intensity of screening. Second, the association is quantified between the
mean lead time and prostate cancer mortality and tested whether it differs between
trials while accounting for differences in screening and diagnosis between arms. We
analyze the individual-level data from PLCO jointly with SEER US population data
to prove that there is no evidence that screening efficacy differed between trials and




This dissertation is motivated by the problem of interpreting recent screening
trials in prostate cancer, the European Randomized Study of Screening for Prostate
Cancer (ERSPC) in Europe and Prostate, Lung, Colorectal, and Ovarian cancer
screening trial (PLCO) in the United States. Introduction of screening for prostate
cancer using the prostate-specific antigen (PSA) biomarker of the disease in the late
80ies led to remarkable dynamics of the incidence of the disease and shortly after,
cancer mortality showed a decline (Schroder et al., 2009, 2012, 2014). Except for
fragmentary studies, no comprehensive information exists on the PSA uptake in the
European countries that would allow specification of utilization intensity by age and
calendar time, which puts forward the problem of estimating PSA utilization patterns
from cancer incidence and mortality data. Even in the USA the patterns have been
heterogeneous and showed nontrivial dynamics. Although prostate cancer mortality
rates in the United States have fallen dramatically since the widespread adoption of
PSA screening in the early 1990s, conclusively establishing screening benefit requires
evidence from randomized controlled trials. Previous studies did not formally evaluate
whether screening efficacy differed between trials when implementation details such
as screening patterns are taken into account.
The ERSPC and PLCO produced apparently conflicting results, with the ER-
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SPC reporting a 21% reduction in prostate cancer mortality (Schroder et al., 2009,
2012, 2014) and the PLCO finding no mortality difference between the trial arms
(Andriole, 2009, 2012). Rather than resolving questions, the trials have exacerbated
long-standing uncertainty about whether screening benefits cancer survival. Indeed
it has been assumed that changes in treatment, rather than PSA screening, largely
explain the observed decline in mortality rates (Chou and LeFevre, 2011). It was
suggested that ad-hoc screening in the control arms of the trials (contamination) was
to blame for the controversial results. Control arms of the trials are thought of as
being representative samples from the respective populations inheriting their popu-
lation screening patterns. However, because subject-level screening schedules in the
control arms as well as in the populations they come from are unobserved, adjust-
ing for contamination is impossible without a proper model-based methodology that
would allow estimation of the distributional characteristics of an ad-hoc screening
utilization process in a population from observed cancer incidence. Devising such
methodology and applying it to cancer registry data and trials data is one focus of
this dissertation.
In the second chapter, we formulate a joint model of cancer progression to symp-
tomatic (clinical) diagnosis and the screening process and the associated detection
mode, as both processes interact to produce the observed incidence in the popula-
tion. The risks of screening and clinical diagnosis are dependent sharing the latent
tumor onset and progression processes in the subject. The model is formulated that
treats both risks semiparametrically on two time scales, age t and calendar time (year)
y. Because the model is developed under the premise of unobserved screening sched-
ules, the screening tests are modelled as an unobserved non-homogeneous Poisson
process Nscr, with intensity hscr that depends on age and calendar time. The model
for the observed data is an average over the unobserved onset time (S), the screening
process (Nscr), and the mode of diagnosis (SDx vs. CDx). This set of unobserved
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random variables and stochastic processes constitutes a complex shared “frailty” ob-
ject that explains the dependence between the competing risks of diagnosis. Intensity
of screening and the hazard driving prostate cancer progression are estimated jointly
and semiparametrically using the NPMLE method based on the joint model. Asymp-
totic and finite sample properties of the proposed estimators are studied analytically
and by simulations. An application using data from the European cancer registry
EUREG is presented.
In the third chapter, we develop a semiparametric joint model of cancer progres-
sion to clinical and screening diagnosis based on screening trials data with a mixture
of known PSA test schedules per protocol and random unknown schedules before and
after implementation of the protocol as well as in the control arm. We analyze the
subject-specific incidence data for both control and screening arms from PLCO. Pa-
tients in the control arm were screened following population patterns while those in
the screening arm were recruited and screened for 6 years according to a specific sched-
ule. The model is formulated under the premise of unobserved screening schedules
(population patterns) for subjects in the control arm and subjects in the screening
arm when they are off trials, with specific screening schedules N scscr following protocols
during trials. The population screening patterns are modeled as an unobserved non-
homogeneous Poisson process N cscr, with intensity hscr that depends on age following
the longitudinal study. For both arms, subjects are assumed to be screened with
the same intensity as the population hscr before they enter trials due to randomiza-
tion. For subjects in the control arm during the trial, the intensity may change if
recruitment into the trial has an effect on subjects’ screening patterns (Gulati et al.,
2012; Pinsky et al., 2010) and the intervention effect persists after subjects exiting
the trial. Hence we set the intensity as r1hscr with the risk ratio r1. For subjects
in the screening arm during the trial, the test schedules are discrete and fixed and
they return to random after exiting the trial with the intensity r2hscr, where the risk
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ratio r2 models the difference v.s. the population intensity. The screening risk ratio
r3 models the difference in screening utilizations between screening arm and control
arm after the trial. In addition, we incorporate incidence data from SEER with con-
trol arm in the absence of screening and intervention arm with screening intensity as
r4hscr. Ad-hoc screening patterns in both arms before recruitment and after existing
the trial, and the hazard driving prostate cancer progression are estimated jointly and
semiparametrically. Hypothesis tests comparing the screening intensities between the
arms and periods using the risk ratios are performed to validate if the contamination
exists. Applications using incidence data from PLCO and SEER are demonstrated.
In the fourth chapter, we derive the mean lead tim (MLT)s to link cancer mortality
to cancer incidence and screening efficacy. The lead time is the amount of time to
cancer diagnosis advanced due to screening, which is a counterfactual concept. We
use a two-step approach to formally test whether screening efficacy differs between
trials with mean lead time. First, the mean lead time is estimated in each trial arm as
a proxy for the intensity of screening. We estimate the MLTs empirically, without any
model assumptions about cancer progression and diagnosis. The empirical approach
estimated the MLTs by calculating the differences between survival curves for time
from randomization to diagnosis in each trial arm relative to an assumed baseline level.
Additionally, one analytic model (UMICH) and two simulation models (FHCRC and
MISCAn) estimated distributions of age at onset of latent disease and diagnosis in
the absence and presence of screening. The fitted model then estimated MLTs as
in the empirical approach but using projected instead of observed incidence data.
Second, the association is quantified between the mean lead time and prostate cancer
mortality and tested whether it differs between trials while accounting for differences
in screening and diagnosis between arms. We analyze the individual-level data from
PLCO jointly with SEER US population data to prove the benefits of screening in
terms of reducing the risk of prostate cancer death.
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CHAPTER II
A Joint Model of Cancer Incidence and Screening
2.1 Introduction
Prostate cancer is the most common cancer in men presenting a significant public
health problem. Since the introduction of prostate specific antigen (PSA) screening
the incidence rates of newly diagnosed prostate cancers have seen a dramatic increase
in Europe (Figure 2.1) that followed country-specific PSA utilization uptake. Shortly
after, cancer mortality showed a decline (Schroder et al., 2009, 2012, 2014). To study
cancer incidence patterns induced by screening Tsodikov et al. (2006) developed a
parametric model of prostate cancer in the US population, relying on PSA utilization
patterns obtained from external studies. Except for fragmentary studies, no direct
data exist on the PSA uptake in the European countries. Because PSA utilization
in a population is a strong factor potentially confounding the results of survival and
screening trials (Lee and Tsodikov, 2013; Gulati et al., 2012), its estimation is an
important problem. In this chapter we propose a model that allows us to estimate
screening utilization indirectly from cancer incidence data.
The screening utilization patterns observed in the USA using claims and survey
data (Mariotto et al., 2007) have been heterogeneous and showed nontrivial dynamics,
which makes their parametric specification for a different population quite challenging


















Figure 2.1: Averaged prostate cancer incidence of key countries enrolled in the European Randomized
Study of Screening for Prostate Cancer (ERSPC), Finland, Italy, Spain, Belgium, Netherlands,
Sweden, Switzerland. Data from the European Cancer Registry (EUREG).
to verify for lack of direct information in the observed data. Therefore, we set on
developing a model where the basic dynamic patterns of disease progression and
screening in the population are specified nonparametrically to avoid bias and be
flexible enough to reproduce nontrivial relationships.
The classical model of cancer natural history describes irreversible transitions
through three consecutive stages: disease-free stage, pre-clinical stage (asymptomatic)
and clinical stage (symptomatic) (Zelen and Feinleib, 1969). The preclinical period in
the absence of screening is called the sojourn time, while the clinical period is survival
post-diagnosis. The end of the disease-free stage is marked by the unobserved event
of tumor onset at the age of S. The end of the preclinical stage is marked by the event
of diagnosis. Cancer incidence in the subject is a result of risk competition of two
modes (causes) of diagnosis, one due to symptoms of the disease (clinical diagnosis,
CDx), and one due to the screening process (screening diagnosis, SDx). The risks are
dependent as neither of them exists before the unobserved shared tumor onset event,
denoted by a shared frailty term A.
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In this chapter, a joint model is formulated that treats both risks semiparamet-
rically on two time scales, age t and calendar time (year) y. Because the model is
developed under the premise of unobserved screening schedules, the screening tests
are modelled as an unobserved non-homogeneous Poisson process Nscr, with intensity
hscr that depends on age and calendar time. The model for the observed data is an
average over the unobserved onset time (S), the screening process (Nscr), the shared
frailty term A and the mode of diagnosis (SDx vs. CDx). This set of unobserved ran-
dom variables and stochastic processes constitutes a complex shared “frailty” object
that explains the dependence between the competing risks of diagnosis.
In Section 2 we define the model and derive its essential distributional characteris-
tics. In Section 3 we derive the likelihood function and the nonparametric maximum
likelihood estimators using an iterative reweighting algorithm (Chen, 2009), and study
its asymptotic properties. We apply the method to cancer registry data in Section
4, and perform a simulation study of the properties of estimators in finite samples.
Finally, we discuss the results in Section 5.
2.2 Statistical Framework
2.2.1 The natural history model without screening
To specify the model in the absence of screening we follow Rice and Tsodikov
(2016) who introduced a semi-parametric joint model of time to terminal event af-
fected by a latent progression event. The idea is similar to the parametric model by
Dejardin et al. (2010). We identify the latent event with tumor onset at the age of
S, and the terminal event with diagnosis at the age of T . By definition, the latent
event must precede the terminal one: S ≤ T . The hazard rate associated with the
r.v. T , dΛ(t|x) = λ(t|x)dt, where t is age at diagnosis (CDx), Λ is the cumulative
hazard, λ is its instantaneous counterpart, and x is the birth year (x = y− t), defines
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cancer incidence on both time scales (t, y). The time to the latent onset event S
follows the Cox model dΛ0(t|Ztx), given covariates Ztx, with predictor θ(Ztx), and
the baseline cumulative hazard H0(t). The terminal event (CDx) follows the Cox
model dΛ1(t|Ztx, S) with predictor η(Ztx) and the baseline cumulative hazard H1(t),
constrained to show zero risk before the latent event by means of a multiplicative
indicator process I(t ≥ S) that depends on the latent r.v. S.
dΛ0(t|Ztx) = lim
ε→0
Pr(S ∈ [t, t+ ε]|S ≥ t, Ztx)
ε
= θ(Ztx)dH0(t), (2.1)
dΛ1(t|Ztx, S) = lim
ε→0
Pr(T ∈ [t, t+ ε]|T ≥ t, S, Ztx)
ε
= I(t ≥ S)η(Ztx)dH1(t). (2.2)
Here I is an indicator function such that I(t ≥ s) = 1 if t ≥ s, and zero otherwise. The
relative relationship between θ and η governs the duration of the sojourn time. Expo-








gives η = η(β;Ztx) = e
β0+Z′txβη and θ = θ(β;Ztx) = e
Z′txβθ . In the sequel we may
suppress some of the arguments for brevity, for example writing η(t) for η(β;Ztx).
Generally, when the conditional hazard function for a survival time T is a stochas-
tic process λ(t), then the marginal survival function G(t) = E[e−
∫ t
0 λ(ξ)dξ], where the
expectation is taken over the random trajectory λ̄(t) of the process λ from 0 to t.
Here and in the sequel the notation F̄t will indicate the trajectory of a function F
on [0, t] as opposed to a single value F (t) at the point t. Extending the formulation
of Rice and Tsodikov (2016) to time-dependent predictors, we obtain the marginal


















The first term in the above expression is the probability of no onset before t. The
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integral of the second term averages the probability of no diagnosis during the sojourn
time [s, t] over the pdf of onset at time s.
2.2.2 The joint model with screening
The screening schedule in the subject is summarized by the [0, t]-trajectory N̄scr(t|x)
of the counting process Nscr(t|x) that counts the number of screens performed on the
subject before the age of t. The dependence on the birth cohort x is needed to ac-
count for variable utilization of screening over calendar time and age. Let α(t|x) be
the sensitivity of a screening test, that is the probability of cancer detection by a
screening test performed at age t, given that cancer is detectable (t > S). Given
a subject’s screening schedule at times τi, the the potential time to SDx survival
function becomes











We introduce the shared frailty term A to explain the dependence between the
two modes of diagnosis in the same subject. The corresponding conditional hazard
functions given tumor onset in terms of two modes of diagnosis are:
Time to CDx : dΛ1(t|Ztx, S, A) = AI(t ≥ S)η(Ztx)dH1(t),
Time to SDx : dΛ2(t|Ztx, S, A,Nscr) = −AI(t ≥ S) log(1− α(t|x))dNscr(t|x).
(2.5)
Assuming that screen counts follow a nonhomogeneous Poisson process with intensity





. Using the Laplace functional
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for any integrable functional argument ϕ. We obtain the marginal survival function
incorporating risks of screening and clinical diagnosis as the expectation over the dis-






















Note that the above expression depends on the screening pattern only through the
product α(ξ|x)dHscr(ξ|x), so that the screening sensitivity is not identifiable jointly
with the screening intensity. From now on we will therefore assume that Hscr absorbs
α.





















and θ(t) = eZ
′
txβθ , η(t) = eβ0+Z
′
txβη . The function Ψ summarizes the dependence be-
tween times to the two potential points of diagnosis (SDx and CDx), and a departure
from additive independent risks expressed by the multiplier to the Ψ in (2.8).
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2.2.3 Censoring Mechanism
In our model, there are latent (tumor onset) and terminal (cancer diagnosis)
events. The time to the latent event S is never observed. By definition above, the
latent event must precede the terminal one: S ≤ T . There is a censoring time Tc
that is independent of S and T , given covariates Z. We observe (T ∗,∆, Z), where
T ∗ = min(T, Tc) and ∆ = I(T
∗ = T ). When ∆ = 1, we have S ≤ T ≤ Tc; otherwise
when ∆ = 0, then either Tc ≤ S or S ≤ Tc ≤ T . Thus under the censoring mechanism
we are unable to tell from observed data whether or not the latent event has occurred.
2.3 Estimation
2.3.1 Likelihood













where R(t|x) is the set of subjects at risk for diagnosis of x-birth cohort at age t,
and dN(t|Z̄txi) is the indicator that subject i from the same risk set was diagnosed at
t. The above likelihood recognizes the life-table-type cross-sectional data structure
resulting from observations of a population at risk of the disease along with the counts
of diagnosis coming from the population, over a period of time. The probability for
a subject at risk to get a diagnosis over the next small period of time dt is dΛ, which
makes the first term of the conditional likelihood. The second term is a log of the
probability to survive without diagnosis for such subject, log(1− dΛ) = −dΛ, where
the differentials are understood as first order terms with respect to dt.
With the appropriate filtration Ft−, for the subject i ∈ R(t|x), we construct the
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orthogonal martingale (at the true model):




2.3.2 Nonparametric Maximum Likelihood Estimation
2.3.2.1 Functional derivative
Denote the functional derivatives of Ψ(t|Z̄tx) from (2.9) w.r.t. dH(τ) (dH0, dH1)









respectively, where the functional derivatives are defined as follows. For a functional








(see Hu and Tsodikov, 2014a, Section 3.2) and correspond to taking the derivative
with respect to a ”jump” of f at time t, where f can be discrete or continuous. For
a linear functional of the form J(f) =
∫ t
0














ϕ(u) dI(u > s) = ϕ(s)I(t ≥ s).




∂dHscr(s|x) = I(t ≥ s),


















2.3.2.2 Score equations and asymptotic properties
Let β = (βθ,βη,βφ) be the parameters with onset, clinical diagnosis, and frailty
parts of the model, respectively. Given the maximum follow-up time υ, differentiate
the log-likelihood we arrive at the following score equations for dH0(τ), dH1(τ), dHscr(τ |x)
































i∈R(τ |x) Ψ(τ |Z̄τxi)ηi(τ)
, ηi(τ) = η(τ |β;Zτxi). (2.15)









Ψ(τ |Z̄τxi)wdHscr(τ |x), (2.16)
where








i∈R(τ |x) Ψ(τ |Z̄τxi)
. (2.17)












It can be shown that the score functions for H0, H1, Hscr are martingales at the true
model (see Appendix A.3.1 for details). For the weighted Breslow-type estimators of
dH1 and dHscr, we note that the weights w = (wdH1 , wdHscr) have expectation of 1,
given filtration Ft− . In particular, the martingale estimation equations (EE) solution
can be obtained by setting all weights to 1. The EE approach provides estimators
that are consistent, computationally fast, yet not fully efficient (Hu and Tsodikov,
2014). The efficiency of the NPMLE is due to the fact that optimal weights depend
on martingale residuals utilizing available information in the future of the subject.
We adapt the Weighted Breslow Estimator algorithm (Chen, 2009) to maximize
the likelihood by iteratively updating the weights. Following Rice and Tsodikov
(2016), we impose a proportional hazards (PH) assumption in the example. Let
dH0 = dH1 = dH, meaning that subject shares the same baseline hazard between
tumor onset and cancer detection by symptoms (CDx). With richer population-
level covariates, independent specification of these baseline hazards would perhaps
be a better choice. With the weights treated as known at the inner loop of the
algorithm, a set of recurrent score equations emerges similar to the computationally
efficient martingale estimating equations (Chen et al., 2002) in the EE approach. An
alternative computation method is the EM algorithm of Tsodikov (2003) that requires
substantial theoretical development for the current model. Given initial values for β
and initial weights w(0) as 1, we use Nelson-Aalen estimator as initial values for
dH and dHscr. For iteration count k = 0, 1, ..., we repeat the following steps until
convergence to maximize the likelihood over the two hazards and obtain the profile
likelihood `pr(β):
1. Fix weights w(k) and given (dH(k), dH
(k)
scr), obtain the solution (dH(k+1), dH
(k+1)
scr )
from the score equations for dH and dHscr.




Maximization of the profile likelihood `pr(β), obtained using the above algorithm,
using general maximization methods such as conjugate gradients, we arrive at the
final MLEs.
Taking derivatives of the score equations w.r.t Ω = (β, dH, dHscr) and plugging
the converged estimators Ω̂, we obtained the observed information matrix J (Ω̂).




























Inverting J (Ω̂) the we can obtain the estimated standard errors of Ω̂ and construct
the confidence bands.
Consistency of the estimators is proved by empirical processes following Zeng and
Lin (2007); Kosorok (2008); Hu and Tsodikov (2014b). Weak convergence is proved
using the martingale structure of the score equations following Chen (2009); Hu and
Tsodikov (2014b). Denote the true value of the set of model parameters Ω by Ω0.
Under regularity conditions, we have the following propositions (see Appendix A.3
for proof):
Theorem II.1. β̂ converges to β0, Ĥ(·) converges to H0(·), Ĥscr(·|x) converges to








to a zero-mean Gaussian process whose covariance function structure is given in Ap-
pendix A.3.
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2.4 Example and Simulation Study
2.4.1 EUREG data analysis
EUREG permits the exploration of geographical patterns and temporal trends
of incidence, mortality and survival observed in European population-based cancer
registries for 35 major cancer entities in about 100 registration areas (EUREG, 2012).
We use the incidence data with cancer cases C and population P corresponding to age
interval [50,89] and calendar year interval [1953-2009] for key countries enrolled in the
European Randomized Study of Screening for Prostate Cancer (ERSPC), Finland,
Italy, Spain, Belgium, Netherlands, Sweden, Switzerland. Incidence of prostate cancer
before the age of 50 is negligibly small.
For the shared frailty A, let A ∼ Γ( 1
φ(Ztx)
, φ(Ztx)), where φ(Ztx) = e
Z′txβφ that rep-
resents a gamma frailty model, a common choice in survival analysis with dependent






−1,L(2)(s) = (1 + φ)(1 + φs)−
1
φ
−2. In the absence of covariates affecting
the tumor onset event, we set θ = 1 and φ(Ztx) = e
βφ . Before the introduction of PSA
screening in the late 80ies, the incidence of prostate cancer had an increasing trend in
calendar time y (Figure 2.1), reportedly partially due to surgical treatment of benign
prostate enlargement (the TURP treatment) (Merrill et al., 1999). To model this
effect, a general linear model is specified for η(β;Ztx) during [1953,1989], saturating




1, y < 1953
eβ1+β2(y−1953), 1953 ≤ y < 1989
eβ1+β2(1989−1953), y ≥ 1989.
(2.20)
With the calendar year y as the only covariate, Z̄txi does not depend on i, given t
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and x. Let P (t|Z̄tx) =
∥∥R(t|x)∥∥, denote the size of the risk set for cohort x at age
t (population) and let C(t|Z̄tx) =
∑
i∈R(t|x) dNi(t|Z̄txi) be the count of cancer cases.
The score equations become
dH(τ) =
C(t|Z̄τx)






P (τ |Z̄τx)Ψ(τ |Z̄τx)wdHscr(τ |x)
− η(τ)dH(τ). (2.22)
Setting β′ = (β1, β2, βφ) = (0.5, 0.5, 0.5) initially, and following the algorithm we
obtain the MLEs β̂, dĤ and dĤscr. Figure 2.2 and Figure 2.3 display the base-
line hazard h driving prostate cancer diagnosis in the absence of screening, and
the screening intensity hscr with the 95% confidence interval for the age 70 group
by year of diagnosis. The wider band for the screening intensity after 2007 is be-
cause of smaller available data for this period. Estimated regression coefficients are
β̂′ = (0.30, 0.20,−0.01), with standard errors SE(β̂′) = (0.009, 0.006, 0.12).
Figure 2.4 and Figure 2.5 display the observed cancer incidence and the predicted
one with PSA screening. Before year 1989, the year trend is modeled through β
parametrically. The prediction in this period is also driven by the nonparametrically
specified H. After 1989, the screening intensity matrix parameter hscr nonparametri-
cally specified by age and calendar time comes into play, and the expected incidence
depends on both age and year semi-parametrically matching the observed incidence.
2.4.2 Simulation study
To assess the finite-sample properties of the parameter obtained by the proposed
methodology, we perform a simulation study. In particular, we verify that the vari-
ance of modeled parameters can be obtained using the observed information matrix



















Hazard of disease by age with 95% CI, EURO
Figure 2.2: Baseline hazard of disease driving diagnosis dH with 95%CI
sampling cancer incidence from the population at risk using Bernoulli trials with
probability dΛ. For each dataset k we obtain the NPMLE estimators Ω̂(k) and the












. Table 1 and Table 2 present the simulation results in terms
of β, dH and dHscr, based on 200 replicates.
We note that β̂φ that describes the frailty term is characterized by much higher
variance than the rest of β, which is generally typical of parameters characterizing
latent model quantities. Same is true regarding the baseline hazard of disease driving
diagnosis dH vs. the intensity of PSA screening dHscr, given that PSA schedules are
not observed in the dataset. The PH assumption linking dH1 and dH0 into a common
dH allowed for the information from observed diagnoses to bear on the latent hazard
of tumor onset. Regarding bias, again we see manifestation of the same effect with
parameters in the latent parts of the model showing larger finite sample bias.
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Table 2.1: Simulation results: Frailty and year trend before screening β and hazard of disease driving
diagnosis dH by age.
Parameters True Bias ESE ASE
β
β1 0.22 0.01 0.009 0.01
β2 0.19 0.00 0.006 0.004
βφ -0.01 0.04 0.12 0.13
dH
55 0.00278 0.00001 9.1× 10−5 9.7× 10−5
60 0.00390 0.00003 9.4× 10−5 1.3× 10−4
65 0.00506 0.00004 9.4× 10−4 1.1× 10−4
70 0.00631 0.00005 9.7× 10−4 9.7× 10−5
75 0.00705 0.00005 1.1× 10−4 1.0× 10−4
80 0.00724 0.00005 1.3× 10−4 1.2× 10−4
85 0.00657 0.00003 1.5× 10−4 1.4× 10−4
ESE: Empirical Standard Errors; ASE:Aysmptotic Standard Errors
Table 2.2: Simulation results: Screening intensity by calendar time dHscr for age=70.
Year True Bias ESE ASE
1995 0.0032 0.0001 0.00067 0.00060
1999 0.0058 0.0007 0.00065 0.00061
2005 0.0123 0.0020 0.00068 0.00062
2009 0.0095 0.0023 0.00492 0.00451



















Screening intensity at age 70 by calender year with 95% CI, EURO
Figure 2.3: Screening intensity dHscr for age 70 with 95%CI
2.5 DISCUSSION
The model we proposed provides a quantitative link between dissemination of
cancer control processes with unknown schedules and their impact on population
and public health measures of cancer incidence. We quantify the relationships that
underlie recent trends in prostate cancer incidence in terms of model parameters
(β, dH, dHscr) and perform inference on these parameters. The model can estimate
screening intensity in a population jointly with the disease natural history and gener-
ate predictions for prostate cancer incidence under a variety of PSA screening patterns
and for the case of no PSA screening (Hscr = 0).
The parameters in our model are estimated from population databases (cancer
registries) in the most challenging situation when neither screening schedules nor the
mode of diagnosis (screening vs. symptoms) are observed. We incorporate random

















Obeserved incidence by age and calender year, EURO
Figure 2.4: Observed prostate cancer incidence of countries enrolled in ERSPC
ing the effects of increased screening utilization on the results of survival and screening
trials. In particular, when trial patients are recruited from the general population,
the model provides guidance on the level of screening occurring in the control arm
(contamination). The methodology of this paper can be extended to estimate con-
tamination of the control arms of screening trials from trial data that are longitudinal
and consist of a mixture of schedules performed per protocol in the screening arm
and random screening occurring in the control arm, before recruitment into the trial,
and after the screening protocol has ended (long term follow-up). The proposed ap-
proach lays the groundwork for model-based joint integrative analysis of population
and trials data in cancer screening, confounded by ad-hoc screening outside of the
control period.
Current approaches to the analysis of screening trials rely on comparisons of mor-
















Expected incidence by age and calender year, EURO
Figure 2.5: Predicted prostate cancer incidence of countries enrolled in ERSPC
mation available from observations of cancer incidence and is subject to effects of
contamination of the control arm. Extending the proposed incidence model to in-
clude survival post-diagnosis and appropriate effects of early detection on survival is
a promising line of future research that could lead to improved power for the effect
of early detection on mortality resulting from better use of the sample information.
Using the extended model, it might also be possible to resolve the conflicting results
of current screening trials in the USA and Europe by careful adjustment for contami-
nation of the control arm, and allowing for some mortality benefit in the control arm
from ad-hoc screening.
The proposed joint model is quite general as it incorporates the most salient
features common to all cancers. As such, it can be applied to other cancers.
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CHAPTER III
Semiparametric Modeling and Analysis of Cancer
Incidence with Cancer Screening Trials
3.1 Introduction
High-quality randomized controlled trials have been demonstrated essential for
evaluating causal effects of medical interventions such as screening for cancer. How-
ever, trials rarely achieve perfect compliance with no contamination. Recent screen-
ing trials in prostate cancer, the ERSPC in Europe and PLCO in the United States,
showed apparently different results. While ERSPC showed a benefit of screening, al-
beit mostly driven by the results from one center, the PLCO trial was non-conclusive
at face value. Prostate cancer incidence in the US was considerably higher than
in Europe before the introduction of screening, likely reflecting earlier adoption of
PSA test diagnosis. The PLCO used shorter screening intervals, had a higher PSA
threshold for biopsy referral and stopped regular screening after 6 rounds. The US
practice setting also contributed to a lower frequency of receipt of biopsy and higher
frequency of routine screening in the control arm compared with the ERSPC. Conse-
quently, comparison of intervention and control arms in the PLCO reflects effects of
an organized screening program relative to opportunistic screening rather than effects
of screening versus no screening. (Berg, 2011; Andriole, 2012)
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In chapter 2 we have built a model that provides a quantitative link between
dissemination of cancer control processes incorporating random PSA test schedules
and cancer incidence. When trial subjects are recruited from the general population,
the model may provide guidance on the level of screening occurring in the control arm
(contamination). In this chapter we aim to develop a model to estimate contamination
of the control arm of screening trials from trial data that are longitudinal and consist
of a mixture of schedules performed per protocol in the screening (intervention) arm
and random screening occurring in the control arm, before recruitment into the trial,
and after the screening protocol has ended (long term follow-up).
Our proposed approach performs model-based joint integrative analysis of popu-
lation and trials data in cancer screening. The model is developed under the premise
of unobserved screening schedules (population patterns) for subjects in the control
arm and subjects in the screening arm when they are off trials, with specific screening
schedules N scscr following protocols during trials. The population screening patterns
are modeled as an unobserved non-homogeneous Poisson process N cscr, with intensity
hscr that depends on age following the longitudinal study. For both arms, subjects
are assumed to be screened with the same intensity as the population hscr before they
enter trials due to randomization. For subjects in the control arm during the trial, the
intensity may change if recruitment into the trial has an effect on subjects’ screening
patterns (Gulati et al., 2012; Pinsky et al., 2010) and the intervention effect persists
after subjects exiting the trial. Hence we set the intensity as r1hscr with the risk ratio
r1. For subjects in the screening arm during the trial, the test schedules are discrete
and fixed and they return to random after exiting the trial with the intensity r2hscr,
where the risk ratio r2 models the difference v.s. the population intensity (see Fig-
ure 3.1 for illustration). The screening risk ratio r3 models the difference in screening
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The model for the observed data is an average over the unobserved onset time (S),
the screening process (N cscr), and the mode of diagnosis (SDx vs. CDx), where the
schedules and mode of diagnosis are unknown.
Population
Control arm Entry Exit
hscr r1hscr r1hscr
Screening arm Entry Exit
hscr Fixed schedule r2hscr
Figure 3.1: An illustration of screening risk (intensity) in different intervals for screening arm and
control arm.
In Section 2 we define the joint models with screening for both control and screen-
ing arms and derive their essential distributional characteristics. In Section 3 we
derive the likelihood function with marked endpoint of diagnosis (SDx or CDx) and
the nonparametric maximum likelihood estimators using the iterative reweighting al-
gorithm (Chen, 2009). We apply the method to PLCO trial data in Section 4. Finally,
we discuss the results in Section 5.
3.2 Statistical Framework
3.2.1 Joint model with screening for the control arm
For control arm, subjects are screened following population pattern of random
schedules with intensity hscr before entering the trial. To specify the joint model
during the trial we follow the semi-parametric joint model of time to terminal event
affected by a latent progression event by Rice and Tsodikov (2016). Similarly, we
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identify the latent event with tumor onset at the age of S, and the terminal event
with diagnosis at the age of T and S ≤ T . The hazard rate associated with the r.v.
T , dΛ(t) = λ(t)dt, where t is age at diagnosis (CDx), Λ is the cumulative hazard, λ is
its instantaneous counterpart. We assume that population screening pattern behind
periods of unobserved screening schedules is stationary (no trend in calender time)
because the trial falls on a relatively short and stable period in calender time. The
time to the latent onset event S follows the Cox model dΛ0(t|Zt), given covariates Zt,
with predictor θ(Zt), and the baseline cumulative hazard H(t). The terminal event
in the absence of screening (CDx) follows the Cox model dΛ1(t|Zt, S) with predictor
η(Zt) and same baseline cumulative hazard H(t), and constrained to show zero risk
before the latent event by means of a multiplicative indicator process I(t ≥ S) that
depends on the latent r.v. S.
dΛ0(t|Zt) = lim
ε→0
Pr(S ∈ [t, t+ ε]|S ≥ t, Zt)
ε
= θ(Zt)dH(t), (3.2)
dΛ1(t|Zt, S) = lim
ε→0
Pr(T ∈ [t, t+ ε]|T ≥ t, S, Zt)
ε
= I(t ≥ S)η(Zt)dH(t). (3.3)
The relative relationship between θ and η governs the duration of the sojourn time.








gives η = η(β;Zt) = e
β0+Z′tβη and θ = θ(β;Zt) = e
Z′tβθ . Still in the sequel we may
suppress some of the arguments for brevity, for example writing η(t) for η(β;Zt).
Let the counting process N cscr(t) count the number of screen tests performed on the
subject by the age of t, with the screening schedule expressed by the [0, t]-trajectory
N̄ cscr(t). With the risks of CDx and SDx competing, we assume that CDx and SDx
are independent given covariates Z̄t, tumor onset S and N̄
c
scr(t). Then the conditional
diagnosis-free survival function is
Gd(t|Z̄t, S, N̄ cscr(t)) = GCDx(t|Z̄t, S)GSDx(t|Z̄t, S, N̄ cscr(t)),
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where GCDx(t|Z̄t, S) = e−
∫ t
0 I(ξ≥S)η(ξ)dH(ξ) is the potential conditional survival function
for time to CDx in the absence of screening from (3.3). Given a subject’s screening
schedule at times τi, the the potential time to SDx survival function becomes











where α is the sensitivity of screening. Let Ae and Ax be the ages of entry into and
exit from the trial protocol respectively. Note that the follow-up period starts at
Ae and generally extends beyond Ax. When subjects enter the control arm of the
trial from the population, the screen counts (assumed to follow a non-homogeneous










. Here r1 is the risk ratio of screening for subjects of
control arm in the trial compared to the population screening intensity. I(ξ ≥ Ae) = 1
if ξ ≥ Ae and I(ξ ≥ Ae) = 0 if ξ < Ae. Using the Laplace functional of a Poisson pro-
cess with intensity (Serfozo (2009); Shiryaev (1960)), we obtain the marginal survival
function incorporating risks of screening and clinical diagnosis as the expectation over
the distribution of latent event time S and screening pattern N cscr for subjects in the
control arm. Let πc(t|Z̄t) be the averaged probability of no diagnosis at time t. For



























The first term in the above expression averages the probability of no diagnosis before
the trial entry, while the second term averages the probability of no diagnosis after

























The sum of the first and second terms in the above expression averages the prob-
ability of no diagnosis before exiting the trial protocol at the age of Ax, while the
third term averages the probability of no diagnosis during the follow-up after Ax. Let
Gcd(t) be the marginal survival function of the time to diagnosis T for the control
arm. Elaborating further on the model quantities we have
Gcd(t|Z̄t) = E
[




0 θ(ξ)dH(ξ) + πc(t|Z̄t), (3.5)



















































s [(η(ξ)−θ(ξ)dH(ξ)+r1α(ξ)dHscr(ξ)]θ(s)dH(s), t > Ax.
(3.7)
The function Ψc summarizes the dependence between times to the two potential
points of diagnosis (SDx and CDx), and a departure from additive independent risks
for subjects in the control arm.
3.2.2 Joint model with screening for the screening arm
In terms of the screening arm, subjects were recruited from the population into
a specific screening schedule N scscr. While the detection mode (CDx or SDx) in the
control arm is unknown, in the screening arm the detection mode is available during
the trial protocol period [Ae, Ax] until loss of follow-up. Let Iscr be the indicator of
diagnosis by screening,
Iscr =
1, screening diagnois,0, clinical diagnosis.
It is natural to assume that subjects in all arms share the same disease natural
history model (in particular, the same hazard function (3.3)). For the screening arm
before Ae and after Ax (period off trial), the intensities of screening are hscr and
r2hscr, respectively. When r1 = 1 and r2 = 1, subjects in all arms, outside of the
period of screening per protocol in the screening arm, have the same intensity as the
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population they were recruited from.
Let πsc(t|Z̄t) be the averaged probability of no diagnosis at time t for subjects in



















































Let Gscd (t) be the marginal survival function of the time to diagnosis T for the
screening arm, and f(t, Iscr = k), k = 0, 1 be the two sub-distribution (crude) proba-
bility density functions (pdf) by mode of diagnosis. Elaborating further on the model
quantities (see Appendix B), we have
Gscd (t|Z̄t) = E
[




0 θ(ξ)dH(ξ) + πsc(t|Z̄t),
f(t, Iscr = 0|Zt) = πsc(t|Z̄t)η(t)dH(t),






α(t)dHscr(t), t < Ae
− log(ᾱ(t))dN scscr(t), Ae ≤ t ≤ Ax
r2α(t)dHscr(t), t > Ax.
The corresponding mode-specific hazards are
dΛ0(t|Zt) =
















































s [(η(ξ)−θ(ξ)dH(ξ)+r2α(ξ)dHscr(ξ)]θ(s)dH(s), t > Ax.
(3.11)
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3.3 Estimation and Hypothesis Testing
3.3.1 Likelihood
The joint log-likelihood function for both control and screening arm is















log dΛIscr(t|Zti)dN Iscr(t|Zti)− dΛIscr(t|Zti)
} (3.12)
where υ is the maximum follow up time, R(t) is the risk set at time t specific to
the arm (c for control, sc for screening), dN(t|Ztj) is the counting process of cancer
diagnosis for subject j. For the screening arm, we adapt the likelihood with marked
endpoint (T, Iscr) from Hu and Tsodikov (2014b). In screening arm, for subject i in
the risk set Rsc(t) at time t, dΛ0(t|Zti) = f(t,Iscr=0|Zti)Gscd (t|Zti) is the crude hazard of clinical
diagnosis; and dN0(t|Zti) is the counting process of clinical diagnosis in subject i.
Similarly, dΛ1(t|Zti) = f(t,Iscr=1|Zti)Gscd (t|Zti) is the crude hazard of screening diagnosis and
dN1(t|Zti) is the counting process of screening diagnosis in subject i. The parameter
set Ω = {β, r1, r2, α,H,Hscr} enters the likelihood through θ, η,Ψc,Ψsc, with observed
data {Rc,Rsc, Iscr, Ae, Ax, N,N scscr}.
With the appropriate filtration Ft− for subject i ∈ Rc(t) or Rsc(t), we construct
the orthogonal martingale at the true model:








∣∣∣Ft−] = dΛIscr(t|Zti), Iscr = 0, 1.
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3.3.2 Score equations















respectively. Given the maximum follow-up time υ, differentiating the log-likelihood
we arrive at the following score equations for dH(τ), dHscr(τ) and β, α(τ), r1, r2, where


































































































































I(τ < Aei)α(τ) + I(τ > Axi)r2α(τ)
] .
(3.18)
























































The scores for β, r1, r2, α(τ) are martingales at the true model, same as the score
functions for H,Hscr(see Appendix B for details). We have the weighted Breslow-type








wscdHscr) that have expectation of 1, given filtration Ft− . The optimal weights depend
on martingale residuals evaluated over the future of the subject ensure the efficiency
of the NPMLE. To enhance the robustness of the parameters in our model, we also
include cancer incidence data from the Surveillance, Epidemiology, and End Results
(SEER, 2017) into the estimating procedure. Data before PSA screening began in
the US can be used to estimate the baseline hazard dH in the absence of screening,
treated as another control arm without screening contamination. While data after
screening test was introduced can be used to estimate the screening risk r4hscr in the
population from SEER, treated as another intervention arm. Here r4 denotes the risk
ratio of screening in the population from SEER.
3.3.3 Estimating algorithm and Hypothesis tests
Similar to Chapter 2, we keep adapting the Weighted Breslow Estimator algorithm
(Chen, 2009) to maximize the likelihood by iteratively updating the weights. While
a set of recurrent score equations emerges similar to the computationally efficient
martingale estimating equations (Chen et al., 2002). The weights are treated as
known at the inner loop of the algorithm. For simplicity we assume constant screening
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sensitivity α. Set initial values for Ω = (β, r1, r2, r4, α) and initial weights w
(0) as 1,
use Nelson-Aalen estimator as initial values for dH and dHscr. For iteration count
k = 0, 1, ..., we repeat the following steps until convergence to maximize the likelihood
over the two hazards and obtain the profile likelihood `pr(Ω):
1. Fix weights w(k) and given (dH(k), dH
(k)
scr), obtain the solution (dH(k+1), dH
(k+1)
scr )
from the score equations for dH and dHscr.
2. Update the weights w(k+1) using (3.16) and (3.18) with (dH(k+1), dH
(k+1)
scr ).
Maximization of the profile likelihood `pr(Ω) is obtained using the above algorithm.
We arrive at the final MLEs with general maximization methods such as conjugate
gradients applied to `pr. Given the MLEs of our proposed estimators, we construct
the likelihood ratio test (LRT) for our hypotheses.
Hypothesis 1. The recruitment into the trial did not change the ad-hoc screening
patterns, control arm.
H0 : r1 = 1 vs. H1 : r1 6= 1
Hypothesis 2. Being on trial’s protocol did not change ad-hoc screening patterns,
screening arm.
H0 : r2 = 1 vs. H1 : r2 6= 1
Hypothesis 3. No difference in ad-hoc screening patterns between arms.
H0 : r3 = 1(r1 = r2) vs. H1 : r3 6= 1
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Hypothesis 4. All ad-hoc screening patterns in the trial are the same as in the
population.
H0 : r1 = r2 = r3 = 1 vs. H1 : at least one ri 6= 1
Hypothesis 5. Population in SEER have the same screening pattern as the general
one.
H0 : r4 = 1 vs. H1 : r4 6= 1
3.4 Data Analysis Example
3.4.1 PLCO and SEER data analysis
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is
a large population-based randomized trial evaluating screening programs for these
cancers. The primary goal of this long-term trial of the National Cancer Institute’s
(NCI) Division of Cancer Prevention (DCP) is to determine the effects of screening
on cancer-related mortality and on secondary endpoints. Ten screening centers lo-
cated across the United States enrolled 76,685 men and 78,216 women, ages 55 to
74, and randomized them to an intervention arm, which received trial screening, or
control arm, which received standard care (can still receive screening test following
the population pattern). Participants included in the intervention arm of the trial
received yearly screening per protocol cancer during their first 6 years of participation
in the trial, and follow-up continued for at least 7 additional years: 39,105 women and
38,340 men were in this part of the trial. In the first 6 years, men received PSA blood
tests. Participants in the control arm were followed for 13 years after enrollment, but
did not receive any planned screening examinations: 38,111 women and 38,345 men
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were in the control arm. Eligibility requirements included age (between 55 and 74
at enrollment), and no previous history of any PLCO cancer (PLCO, 2016). To fit
the model we use the incidence data of both control and screening arms from PLCO
trial, including age at randomization, age at diagnosis, screening schedule and mode
of diagnosis during the protocol phase and follow-up time for both arms.
The Surveillance, Epidemiology, and End Results (SEER) Program of the National
Cancer Institute provides information on cancer statistics in an effort to reduce the
cancer burden among the U.S. population. SEER is supported by the Surveillance
Research Program, which provides national leadership in the science of cancer surveil-
lance as well as analytical tools and methodological expertise in collecting, analyzing,
interpreting, and disseminating reliable population-based statistics (SEER, 2017). We
use cancer incidence data from 9 main cancer registries. The SEER 9 registries are
Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland,
Seattle-Puget Sound, and Utah. Data are available for cases diagnosed from 1973
and later for these registries with the exception of Seattle-Puget Sound and Atlanta.
The Seattle-Puget Sound and Atlanta registries joined the SEER program in 1974
and 1975, respectively. For the control arm, we use cancer incidence data with pop-
ulation by age from 1982-1986, just before PSA screening began in the US. And for
the intervention arm data is from 1991-2001.
Set θ = eZ
′βθ = 1, η = eβ0+Z
′βη = eβ0 , and initial values β0 = 0.5, α = 0.9, r1 =
1, r2 = 1, r4 = 1. Following the algorithm we obtain the MLEs η̂, ˆ(α), r̂1, r̂2, r̂3, r̂4,
dĤ, dĤscr. Table 3.1 summarizes the MLEs with 95%CI from the likelihood ratio
tests. The estimated screening sensitivity α̂ = 0.87, that is when a patient is receiv-
ing a screening test, the chance of having positive result is 87%, given tumor onset.
This is consistent with Gulati et al. (2010). r̂1 = 1.04, 95%CI=(0.94,1.14). Within
the trial control arm, the screening intensity is slightly yet not significantly higher
during the trial compared with the population screening pattern, reflecting the oppor-
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tunistic screening pattern (Berg, 2011; Andriole, 2012). r̂2 = 3.04, 95%CI=(2.89,3.19)
indicates that the screening intensity in the screening arm after 6 years is significantly
higher than that in the population, approximately three times higher screening risk
than the population pattern, which reflects the non-compliance and contamination
that were previously described in Gulati et al. (2012). r̂4 = 0.94, 95%CI=(0.92,0.95)
shows that the screening intensity in the population from SEER is slightly lower than
the general population. Table 3.2 summarizes the Hypotheses testing results. The re-
cruitment into the trial did not change the ad-hoc screening patterns for control arm
(Hypothesis 1); while being on trial’s protocol did change ad-hoc screening patterns
for screening arm (Hypothesis 2); there exists significant difference in ad-hoc screen-
ing patterns between arms (Hypothesis 3); ad-hoc screening patterns in the trial are
different from the population (Hypothesis 4); screening risk in the population from
SEER is slightly lower from the general population pattern (Hypothesis 5).
Table 3.1: Maximized likelihood estimators with 95%CI
Parameter µ̂ 95%lower 95%upper
η 1.73 1.71 1.75
α 0.87 0.86 0.88
r1 1.04 0.94 1.14
r2 3.04 2.89 3.19
r4 0.94 0.92 0.95
η: predictor for terminal event; α: screening test sensitivity
Table 3.2: Hypotheses testing results of screening risk ratios
Hypothesis χ2 DF P-value
r1 = 1 0.61 1 0.43
r2 = 1 710.54 1 < 0.0001
r3 = 1(r1 = r2) 245.86 1 < 0.0001
r1 = r2 = r3 554.25 2 < 0.0001
r4 = 1 61.47 1 < 0.0001
DF : degree of freedom; χ2 statistics from Likelihood ratio test
Figure 3.2 displays the incidence comparison between arms and within arms for
PLCO trial. Observed incidence in the screening arm is higher than that in the
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control arm and merge at age 80, showing continued elevated incidence for older
ages with the introduction of PSA testing. If subjects in the screening arm resumed
screening pattern as the population after trial’s 6-year intervention period (r2 = 1),
the incidence would be still higher than the control arm, but lower than observed
incidence in screening arm (null predicted incidence, screening arm, PLCO). While
subjects in the control arm resumed screening pattern as the population after trial’s
follow up period, the incidence is approximately the same as the observed one (null
predicted incidence, control arm, PLCO). In terms of model fit, the observed and
predicted incidence of both arms match well in Figure 3.2. Figure B.1 in Appendix
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Figure 3.2: Observed incidence and predicted incidence by age for PLCO trial; null incidence with
risk ratio as 1.
Figure 3.3 displays the incidence comparison between arms and within arms of
SEER. Observed incidence in the screening arm is higher than that in the control
arm and converge at age 80, showing continued elevated incidence for older ages with
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the introduction of PSA testing. When subjects in the screening arm follow the
same screening pattern as the population (r4 = 1), the incidence is approximately
the same as the observed one (null predicted incidence, screening arm, SEER). The
observed and predicted incidence of both arms match well in Figure 3.3. Figure B.2
in Appendix B is the corresponding Kaplan-Meier curves associated with subjects’
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Figure 3.3: Observed incidence and predicted incidence by age for SEER; null incidence with risk
ratio as 1.
3.5 DISCUSSION
The model we formulated provides a quantitative link between screening with a
combination of unknown and random population pattern and specific trial known
schedules and their impact on cancer incidence. We quantify the relationships and
differences in prostate cancer incidence between arms in both PLCO trial and SEER
in terms of model parameters (β, α, r1, r2, r3, r4, dH, dHscr) and perform inference on
these parameters. The model can estimate ad-hoc screening intensity (contamination)
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jointly with the disease natural history, given specific screening schedules for cancer
screening trials during the protocol phase, and perform hypotheses tests of screening
intensities between and within intervention and control arms.
The model can assess the effects of screening intended utilization and unintended
contamination on the results of survival and screening trials. In particular, when trial
patients are recruited from the general population, the model evaluates the level of
screening occurring in the control arm and after the protocol phase in the screening
arm (contamination) using trial data that are longitudinal follow-up and consist of
a mixture of periods of known and unknown schedules. The proposed approach can
easily be extend to perform model-based joint integrative analysis of population and
trials data in cancer screening settings.
Current marginal approaches to the analysis of screening trials rely on compar-
isons of mortality between arms but fail to utilize the information available from
observations of cancer incidence. Mostly importantly, they fail to adjust for unin-
tended screening contamination. The proposed joint model gives the foundation for
the analysis of mortality and the effects of early detection on survival, adjusted for
contamination. With the extended models, it might be possible to resolve the conflict-
ing results of current screening trials in the USA and Europe by careful adjustment
for contamination of the control arm, and allowing for some mortality benefit in the
control arm from ad-hoc screening.
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CHAPTER IV
Marginal Analysis of Cancer Screening Effect on
Mortality Adjusting for Screening Contamination
4.1 Introduction
More than two decades after prostate-specific antigen (PSA) screening for prostate
cancer entered clinical practice, the US Preventive Services Task Force (USPSTF)
determined there was very low probability of preventing a death from prostate cancer
in the long term and recommended against routine use of the test (Moyer and Force,
2012). Since then, PSA screening rates and prostate cancer incidence rates in the
United States have declined significantly (Jemal et al., 2015, 2016).
The USPSTF recommendation relied heavily on results from the European Ran-
domized Study of Screening for Prostate Cancer (ERSPC; ISRCTN49127736) and the
Prostate, Lung, Colorectal, and Ovarian cancer screening trial (PLCO; NCT00002540).
However, the trials produced apparently conflicting results, with the ERSPC report-
ing a 21% reduction in prostate cancer mortality (Schroder et al., 2009, 2012, 2014)
and the PLCO finding no mortality difference between the trial arms (Andriole, 2009,
2012). Interpreting results of these trials is complicated by differences in their imple-
mentations, including design and adherence, and practice settings. The PLCO used
shorter screening intervals (annual screening versus every 2-4 years), had a higher
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PSA threshold for biopsy referral (4.0 g/L versus 3.0 g/L in most ERSPC centers
and rounds), and stopped regular screening after 6 rounds. Prostate cancer incidence
in the US was higher than in Europe before the trials started, reflecting different pop-
ulations and clinical diagnosis patterns. The US practice setting also contributed to a
higher frequency of screening in the control arm and a lower frequency of biopsy com-
pared with the ERSPC. Consequently, the PLCO compared effects of an organized
screening program relative to opportunistic screening rather than effects of screening
versus no screening (Berg, 2011; Andriole, 2012; Pinsky et al., 2016). Nonetheless,
the PLCO results have been viewed as more relevant to the US setting.
The perceived inconclusiveness of the trial results about screening efficacy persists
despite studies indicating that differences in their implementation might explain at
least some of the variability in their results. A prior investigation by Gulati et al.
(2012) indicates that the trial results may be more consistent than they appear.
However, these studies did not formally evaluate whether screening efficacy differed
between trials when implementation details such as screening patterns are taken into
account. In this chapter we use a two-step approach to formally test whether screening
efficacy differs between the ERSPC and PLCO using mean lead time as a surrogate of
screening intensity. Lead time is the time by with diagnosis of cancer is advanced due
to screening in patients who would be detected anyway in the absence of screening
tests, can be expressed by TCDx−TSDx where T is the r.v of time to diagnosis (Tsodikov
et al., 2006). First, the mean lead time is estimated in each trial arm as a proxy for
the intensity of screening. Second, the association is quantified between the mean
lead time and prostate cancer mortality and tested whether it differs between trials.
The objectives of this chapter are to (1) formally test whether the effects of screen-
ing on prostate cancer mortality differed between the ERSPC and PLCO after ac-
counting for differences in implementation and practice settings and (2) to estimate
the effects of screening in both trials relative to no screening.In Section 2 we derive
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the mean lead time based on the semiparametic transformation model for screening.
In Section 3 we fit the regression model of cancer mortality with prediction of mean
lead time given trials and SEER data. Finally, we discuss the results in Section 4.
4.2 Methods
This study used individual records from both trials in a collaboration between
trial investigators and the Cancer Intervention and Surveillance Modeling Network
(CISNET) prostate cancer working group. In the intervention arms, these records
included age and year of randomization, enrollment center, dates and results of PSA
tests and rectal exams, whether biopsy was performed, date of cancer diagnosis, and
date and cause of death. In the control arms, the records included age and year
of randomization, enrollment center, date of cancer diagnosis, and date and cause
of death. For consistency with prior publications, ERSPC data included men aged
55-69 years at randomization, while PLCO data included men aged 55-74 years at
randomization.
We first examined a traditional statistical analysis that combined data from both
trials and compared hazards of prostate cancer death in the intervention versus con-
trol arms adjusting for participant age and trial setting. However, this analysis is
questionable due to remaining differences in implementation between trials. To over-
come this limitation, we also examined extended analyses that accounted for variable
screening and diagnostic workup (hereafter screening intensity) in each trial arm,
which we operationalized in terms of mean lead times (MLTs). The MLTs quan-
tify the magnitude of increased prostate cancer incidence relative to a baseline level
expected in the absence of screening, thus capturing differences in both design and
adherence (see below). We estimated the MLTs both empirically and using analytic
or microsimulation models; using multiple approaches allowed us to assess robustness
of results to this uncertain quantity.
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4.2.1 Estimating mean lead times
Lead time is usually defined as the amount of time by which clinical diagnosis (i.e.,
diagnosis without screening) is advanced by screening. In this chapter we define:
LT =
 0, TCDx ≤ TSDxTCDx − TSDx, TCDx > TSDx. (4.1)
Here TCDx is the time from randomization to clinical diagnosis and TSDx is the time
from randomization to screen detection. Under complete follow-up (i.e., where all
pre-clinical cases are eventually diagnosed in the no-screening setting), the MLT cor-
responds to the difference in areas under two survival curves for time from random-
ization to diagnosis (mean survival time to diagnosis): one in the absence of screening
minus one in the presence of screening . From (4.1)
MLT = E
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Under limited follow-up time Tmax, we can define a restricted version of the MLT
as an analogous difference in areas under survival curves up to a specified time point
(Uno et al., 2014). Restricting to the duration of the trial recognizes that events after
the trial period cannot affect the mortality during the trial. Specifically, the time of
screen detection becomes T
′
SDx = min(Tmax, TSDx),and the time of clinical diagnosis
becomes T
′
CDx = min(Tmax, TCDx). To make estimates between trials comparable,








































where GCDx is the survival function for time to clinical diagnosis in the absence of
screening and Gd is the survival function for time to diagnosis with screening.
Finally, to standardize the measure across trial arms in this study, we scaled each
estimated MLT by a common baseline probability of (screen or clinical) diagnosis
during follow-up Tmax, making the MLT a conditional average given any mode of







Please not that this version of lead time is only defined in patients who are detected
by screening and who, in the absence of screening, would be clinically diagnosed. This
definition excludes overdiagnosed patients (i.e., patients detected by screening who
would not be clinically diagnosed in the absence of screening), patients clinically
diagnosed, and patients without any diagnosis. Our goal here, however, is to derive a
generic surrogate of the intensity of screening and diagnosis in a given population that
is amenable to empirical (model-free, robust) estimation and prediction. Nevertheless,
due to its close theoretical relationship with the mean lead time (described below),
we adopt this terminology.
In a screening trial, the time from randomization to screen detection and the
time from randomization to clinical diagnosis are competing risks that are never
both observed for the same patient. Consequently, their full joint distribution is
non-identifiable without specific modeling assumptions (Tsiatis, 1975). However, the
mean lead time (i.e., the mean time difference TCDx − TSDx , which is non-zero only
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if TSDx < TCDx) is identifiable and can be calculated empirically.
Note that our estimates of the MLTs are different from other estimates in the
literature that can be interpreted as the average time by which screening advances
diagnosis among cases that would have been clinically diagnosed (Draisma et al.,
2009). Our MLTs are designed to represent proxies for the intensity of screening and
diagnosis, with higher values reflecting higher attendance rates at screening exams,
more frequent screening exams, less conservative criteria for biopsy referral, and/or
higher frequencies of biopsy. Thus, accounting for variable MLTs across trial arms
captures in a single measure important differences in the trial screening protocols,
participant adherence to those protocols in the intervention arms, and control arm
screening. We estimated the MLTs empirically, without any model assumptions about
cancer progression and diagnosis, and also using three models of cancer natural his-
tory and diagnosis. The empirical approach estimated the MLTs by calculating the
difference between survival curves for time from randomization to diagnosis in each
trial arm relative to an assumed baseline level. The assumed baseline probability
of diagnosis in the absence of screening was derived using incidence rates from the
Surveillance, Epidemiology, and End Results (SEER) program in 1986, just before
PSA screening began in the US, adjusted to reflect distributions of age at random-
ization in each trial. Additionally, one analytic model (UMICH) and two simulation
models (FHCRC and MISCAN) estimated distributions of ages at onset of latent dis-
ease and diagnosis in the absence and presence of screening using individual patient
attendance, screening, and incidence data. The fitted models then estimated MLTs
as in the empirical approach but using projected instead of observed incidence rates.
Additional details are described in the Supplementary Materials C.
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4.2.2 Effects of screening on prostate cancer mortality
We used Cox regression to model survival from randomization to prostate cancer
death, censoring individuals who died of other causes or were alive at last follow-up.
We examined both a traditional statistical analysis and extended analyses that incor-
porated the measure of screening intensity captured by the estimated MLTs. Both
types of analysis included participant age at randomization and a trial setting indi-
cator (PLCO versus ERSPC), which allowed for a different baseline risk of prostate
cancer death in the absence of screening between the two trial settings.
4.2.2.1 Traditional statistical analysis
We first conducted a traditional analysis to test whether the effect of screening
differed between trials. Specifically, we tested the effect of being randomized to the
intervention arm (relative to the control arm) on the risk of prostate cancer death
and all cause of death. For the prostate specific survival model, the exponential of the
coefficient for the trial arm indicator is the hazard ratio for prostate cancer death in
the intervention arm relative to the control arm; in other words, it reflects the effect
of screening on prostate cancer mortality in an intent-to-screen analysis. We fitted
this model with and without allowing separate effects of screening in each trial (i.e.,
with and without interaction between the trial arm and trial indicator), then used a
likelihood ratio test to evaluate evidence of differential effects of screening between
trials.
4.2.2.2 Extended statistical analysis
Next we replaced the trial arm indicator with the corresponding MLT estimated
empirically or using a model-based approach and fit both prostate specific survival
model and overall survival model with all cause of death. For the prostate specific
survival model, the exponential of the coefficient for the MLT represents the hazard
49
ratio for prostate cancer death per additional year of MLT; in other words, it reflects
screening efficacy standardized by screening intensity. As in the traditional analy-
sis, we fitted this model with and without allowing separate effects of screening on
prostate cancer mortality in each trial (i.e., with and without interaction between the
MLT and trial indicator), then used a likelihood ratio test to evaluate evidence of
differential effects of screening between trials. Our extended analyses are consistent
with the analyses in the trial publications (Schroder et al., 2009; Andriole, 2009) with
two important differences. First, rather than relying on an intent-to-treat effect of
screening determined by the assigned arm in a single trial, we explicitly included a
covariate (MLT) to capture the intensity of screening in each arm. This represents a
transition from thinking about screening as all or nothing, corresponding to an inter-
vention and control arm, to a continuous metric of screening intensity, with resulting
coefficient estimates interpreted relative to a no-screening setting (i.e., a setting where
MLT=0). Second, we used combined data from both trials in a single analysis, adding
an indicator for trial to capture differences between trials in baseline cancer-specific
survival without screening and an interaction term to test whether screening efficacy
(per year of MLT) differed between trials.
4.3 Data Analysis
Table 4.1 summarizes participants, follow-up, and prostate cancer cases and deaths
in the two trials using all available follow-up and restricted to 11 years of follow-
up. The data under all available follow-up differ modestly from published results
(Schroder et al., 2009; Andriole, 2012) due to additional cleaning and updating.
Nonetheless, the cleaned and updated data restricted to 11 years of follow-up yielded
values similar to published prostate cancer incidence rate ratios (PLCO: 1.12 vs 1.12;
ERSPC: 1.68 vs 1.63) and mortality rate ratios (PLCO: 1.02 vs 1.09; ERSPC: 0.79
vs 0.79) and preserve the greater effects of screening on prostate cancer incidence and
50
mortality rates in the ERSPC relative to the PLCO.
Table 4.1: Summary of participants, follow-up, and prostate cancer cases and deaths in the ERSPC
and PLCO under all available follow-up or restricted to 11 years of follow-up.
ERPSC PLCO
Control Screening Control Screening
No. of participants 88,921 72,473 38,343 38,340
Age at randomization (years)
median 59 60 62 62
range 55-69 55-69 55-74 55-74
All available follow-up
Follow-up from randomization (years)
median 11.0 11.1 12.5 12.5
range 0.4-17.5 0.4-17.3 0.0-13.0 0.0-13.0
No. of prostate cancer cases 5,398 6,967 4,040 4,430
Person-years of follow-up for incidence 933,854 740,775 403,955 400,008
No. of deaths 17,019 13,652 7,149 6,940
other causes 16,557 13,353 7,003 6,788
prostate cancer 462 299 146 152
Person-years of follow-up for mortality 990,678 827,148 426,720 427,824
Restricted to 11 years of follow-up
Follow-up from randomization (years)
median 11.0 11.0 11.0 11.0
range 0.4-11.0 0.4-11.0 0.0-11.0 0.0-11.0
No. of prostate cancer cases 4,961 6,586 3,641 4,038
Person-years of follow-up for incidence 868,834 686,766 368,844 365,129
No. of deaths 13,207 10,397 5,880 5,798
other causes 12,822 10,150 5,771 5,687
prostate cancer 385 247 109 111
Person-years of follow-up for mortality 890,581 725,997 387,027 387,861
ERSPC=European Randomized Study of Screening for Prostate Cancer; PLCO=Prostate, Lung, Colorectal,
and Ovarian cancer screening trial
To compare the screening intensity in the intervention and control arms of the
two trials, Figure 4.1 illustrates MLTs estimated empirically or using a model-based
approach. All estimation approaches found similar ordering and relative magnitudes
of MLTs across trial arms. The ERSPC and PLCO intervention arms had similar
MLTs, while the PLCO control arm had substantially longer MLTs than the ERSPC
control arm, consistent with more intensive screening (i.e., greater contamination) in
the PLCO control arm. Table 4.2 reports results of the traditional analysis. A like-
lihood ratio test associated with this analysis modestly suggested different effects of
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Figure 4.1: Estimated mean lead times (years) in the intervention and control arm of the ERSPC and
PLCO relative to a hypothetical no-screening setting (where lead time is always zero). Estimated
MLTs are visualized as increasing to the left to suggest the extent to which prostate cancer diagnosis
is advanced by more intensive screening and diagnostic workup.
screening on mortality between trials (P=0.09). Under a common effect of screening,
screening was estimated to reduce the risk of prostate cancer death by 16% (95% CI
4-27%; P=0.01) after accounting for different baseline risks of prostate cancer death
in the PLCO setting relative to the ERSPC setting and participant age at random-
ization. This result essentially corresponds to a weighted average of the effect in each
trial with the relative sizes of the trials as weights.
Table 4.2 also presents our extended analyses, which account for the MLT in each
trial arm estimated empirically or using a model-based approach. The analyses are
highly consistent and indicate no evidence of different effects of screening on mortal-
ity between trials (P=0.37-0.47 for interaction, range across estimation approaches).
Under a common effect of screening, all approaches indicated strong evidence that a
longer MLT was associated with a lower risk of prostate cancer death after account-
ing for differential baseline risks of prostate cancer death between trial settings and
participant age at randomization (P=0.0027-0.0032). These analyses showed that
screening was estimated to confer a 7-9% lower risk of prostate cancer death per year
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Table 4.2: Results of traditional and extended Cox regression analyses of prostate cancer death and
estimated mortality reductions in the settings of the ERSPC and PLCO intervention arms relative
to no screening.
Estimated mortality reduction relative to no screening
Cox regression analysis Setting of ERSPC intervention arm Setting of PLCO intervention arm
Covariate HR 95% CI P MLT Reduction 95% CI MLT Reduction 95% CI
Traditional analysis
PLCO setting 0.53 (0.45-0.62) <0.0001
Age 1.13 (1.11-1.14) <0.0001
Intervention arm 0.84 (0.73-0.96) 0.0099 n/a 16% (4-27%) n/a 16% (4-27%)
Extended analyses
Empirical PLCO setting 0.57 (0.48-0.67) <0.0001
Age 1.13 (1.11-1.14) <0.0001
MLT 0.92 (0.87-0.97) 0.0027 3.96 29% (11-43%) 4.02 29% (11-44%)
FHCRC PLCO setting 0.58 (0.49-0.69) <0.0001
Age 1.13 (1.11-1.14) <0.0001
MLT 0.93 (0.88-0.97) 0.0029 4.00 27% (10-40%) 4.10 27% (10-41%)
MISCAN PLCO setting 0.63 (0.51-0.77) <0.0001
Age 1.13 (1.11-1.14) <0.0001
MLT 0.92 (0.87-0.97) 0.0032 3.49 25% (9-38%) 4.62 32% (12-47%)
UMICH PLCO setting 0.57 (0.48-0.68) <0.0001
Age 1.13 (1.11-1.14) <0.0001
MLT 0.91 (0.85-0.97) 0.0029 3.83 31% (12-45%) 4.01 32% (12-47%)
HR=hazard ratio; CI=confidence interval; PLCO setting=indicator of PLCO setting relative to the ERSPC
setting to account for differential baseline risk of prostate cancer death; Age=participant age at randomization
(continuous); Intervention arm=indicator of randomization to intervention arm; MLT=mean lead time (continuous)
estimated in each trial arm by the specified estimation approach; FHCRC=Fred Hutchinson Cancer Research Center;
MISCAN=Erasmus University Medical Center Microsimulation Screening Analysis; UMICH=University of Michigan
of MLT. Let Rrisk be the risk reduction in the expected risk of prostate cancer death
by lead time, using the formula
Rrisk = 1−HRMLT , (4.6)
this would translate into an estimated 25-31% and 27-32% reduction in the expected
risk of prostate cancer death in the setting of screening as performed in the ERSPC
and PLCO intervention arms, respectively, over 11 years of follow-up relative to no
screening.
Table 4.3 presents both traditional and extended analyses of all cause of death
survival models, accounting for the MLT in each trial arm estimated empirically
or using a model-based approach. The analyses are highly consistent and indicate
no evidence of different effects of screening on mortality of all death between trials
(P=0.36-0.91 for interaction, range across estimation approaches). Under a common
effect of screening, all approaches indicated that a longer MLT was associated with a
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slightly lower risk of prostate cancer death (hazard ratio 0.96-0.98) after accounting
for differential baseline risks of cancer death between trial settings and participant
age at randomization. These analyses showed that screening test reduced the risk of
prostate cancer death specifically, instead of all cause of cancer death.
Table 4.3: Results of traditional and extended Cox regression analyses of all cause of cancer death.
Cox regression analysis
Covariate HR 95% CI P-value
Traditional analysis
PLCO setting 0.53 (0.52-0.54) <0.0001
Age 1.10 (1.09-1.11) <0.0001
Intervention arm 0.96 (0.94-0.98) <0.0001
Extended analyses
Empirical PLCO setting 0.54 (0.53-0.55) <0.0001
Age 1.10 (1.09-1.11) <0.0001
MLT 0.98 (0.97-0.99) <0.0001
FHCRC PLCO setting 0.54 (0.53-0.55) <0.0001
Age 1.10 (1.09-1.11) <0.0001
MLT 0.98 (0.97-0.99) <0.0001
MISCAN PLCO setting 0.55 (0.53-0.56) <0.0001
Age 1.10 (1.09-1.11) <0.0001
MLT 0.98 (0.97-0.99) <0.0001
UMICH PLCO setting 0.53 (0.52-0.55) <0.0001
Age 1.10 (1.09-1.10) <0.0001
MLT 0.97 (0.96-0.98) 0.0029
HR=hazard ratio; CI=confidence interval; PLCO setting=indicator of PLCO setting relative to the ERSPC setting
to account for differential baseline risk of cancer death; Age=participant age at randomization (continuous);
Intervention arm=indicator of randomization to intervention arm; MLT=mean lead time (continuous) estimated in
each trial arm by the specified estimation approach; FHCRC=Fred Hutchinson Cancer Research Center;
MISCAN=Erasmus University Medical Center Microsimulation Screening Analysis; UMICH=University of Michigan
Figure 4.2 illustrates prostate cancer survival from randomization in each trial
arm obtained by Kaplan-Meier estimation and predicted under a common effect of
screening given MLTs estimated by the empirical approach. Predictions obtained
using MLTs estimated by the model-based approaches (not shown) are similar. The
predicted curves closely reproduce observed differences in prostate cancer survival
between the intervention and control arms in both trials, showing that screening
intensity as captured by the MLT is highly informative about between-arm differences
54
in risks of prostate cancer death in both trials.
Figure 4.2: Prostate cancer survival from randomization in the ERSPC and PLCO estimated by
Kaplan-Meier or Cox regression model using mean lead time estimated by the empirical approach.
4.4 Discussion
The USPSTF is currently updating its recommendations about PSA screening
and it has looked at the ERSPC and PLCO at the main sources of evidence about
screening benefit in the past. Primary publications from these high-quality random-
ized controlled trials are irreplaceable for evaluating causal effects of screening for
prostate cancer. Yet analyses like the one in this article that attempt to overcome
limitations of traditional statistical analyses critically complement the empirical trial
findings, including informing about whether the evidence from the trials is compat-
ible and about the expected reduction in prostate cancer mortality relative to no
screening.
Rather than comparing the trial arms as if they represent screened and non-
screened populations, this study estimated the intensity of screening in each arm rel-
ative to no screening. This framework allowed us to formally assess whether screening
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effects differed between the trials when accounting for differential screening intensity
between arms in each trial. By decoupling screening intensity from trial arm labels
and investigating how benefit depends on screening intensity, we concluded that dif-
ferences between the ERSPC and PLCO results are largely attributable to differences
in screening intensities between arms within each trial. Finding no evidence of differ-
ent effects of screening on prostate cancer mortality between trials given the screening
intensities, we estimated a common effect of screening on mortality using pooled data
on 19,226 prostate cancer cases. The pooled estimate demonstrates a highly signifi-
cant benefit of screening. This is the first time that data from both trials have been
harnessed to estimate screening benefit.
It is possible that this analysis had insufficient power to detect a significant differ-
ence in screening efficacy between trials. Thus, while there is no evidence of different
screening efficacies, we cannot unequivocally conclude they were identical. Neverthe-
less, our combined analysis of both trials permits the most powerful examination of
this question to date.
Our analysis indicates that the baseline risk of prostate cancer death differed
between trials. This could be due to different incidence, stage distributions, and
treatment patterns in the trial populations in the absence of screening. A lower-than-
expected mortality (relative to pre-PSA-era survival) was observed in the PLCO,
possibly due to participants being healthier or reflecting an era with improved disease-
specific survival (Pinsky et al., 2007). By quantifying screening efficacy as a func-
tion of screening intensity, we projected that screening lowered the expected risk of
prostate cancer mortality in both PLCO arms.
We used multiple approaches to estimate screening intensity. The empirical ap-
proach reflects catch-all differences in the risk of prostate cancer diagnosis between
arms and calculates the MLT most consistent with incidence in each arm relative to
a common baseline level. In contrast, the model-based approaches explicitly account
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for trial protocols and practice settings details that are known or can be quantified,
e.g., age distributions, enrollment and attendance patterns, and screening and biopsy
frequencies within each ERSPC center. As expected, the estimates are shorter than
in other studies (Draisma et al., 2009) due to the different estimation approach and
because we restricted to 11 years of follow-up. In general, results are highly consistent
across estimation approaches and suggest robustness of our conclusions to these ways
of estimating screening intensity.
The finding that effects of screening on mortality appear to be consistent between
trials after accounting differences in implementation and practice setting corroborate
other analyses. For example, a prior investigation of the PLCO found that control arm
screening substantially limited the power of that trial to detect a clinically important
reduction in prostate cancer mortality (Gulati et al., 2012). However, that study
did not formally evaluate whether effects of screening on prostate cancer mortality
differed between the ERSPC and PLCO when implementation and setting details are
taken into account.
A limitation of this study is that we do not explicitly account for differences be-
tween trials in characteristics of cancer cases (e.g., clinical stage or Gleason score) or
primary treatments. Any differences in these factors between trials will be absorbed
into the trial-specific baseline risks of prostate cancer death. Also, the model-based
approaches to estimate lead times assume that cancers are progressive, although they
allow heterogeneity in progression risk across individuals. Ultimately, it is impossible
to know whether some cancers could remain indolent indefinitely or regress sponta-
neously and permanently. However, all estimation approaches closely match incidence
trends in each trial arm. We also assume that incidence in the absence of screening
was constant across calendar years before and after the trials began. This too is a
simplification. Finally, we consider only the mean lead time as a surrogate for screen-
ing intensity. It is possible that other metrics could have different associations with
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risk of prostate cancer death than we found.
In conclusion, taken together, the data from the two screening trials do not pro-
vide evidence that screening efficacy differed between the ERSPC and PLCO after
accounting for differences in implementation between arms in the trials. Our estima-
tion results of the common effect of screening suggest that screening can significantly
reduce the risk of prostate cancer death. However, as for all interventions, the benefit




Conclusion and Future Work
In this dissertation, we have formulated cancer incidence and mortality models
by incorporating cancer screening patterns with disease progression to the events of
cancer diagnosis and death. With these model-based methodologies, we are able to
estimate cancer screening effect on both cancer incidence and mortality using cancer
registries and screening trial data, especially when the screening patterns are ran-
dom and unobserved. Instead of intent-to-screen analysis, which is less powerful to
evaluate causal effect of cancer screening on reducing risk of death and prolonging
post-diagnosis survival with screening contamination in the control arm, we proposed
the term mean lead time to quantify the screening intensities and estimate the screen-
ing efficacy after adjusting for the contamination. The mean lead time is predicted
by the incidence models with diagnosis-free survival functions with and in the ab-
sence of screening, incorporated with both disease progression features and screening
patterns.
In Chapter II, we have proposed a general model to quantitatively link cancer
control processes in the population with unknown schedules to the impact on cancer
incidence, jointly with the disease natural progression stages. Three baseline risks
are nonparametrically specified to the latent tumor onset (S), cancer detection by
symptoms (CDx) and screening (SDx) respectively. Given tumor onset, the two
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modes of diagnoses are dependent with a shared frailty term A. We demonstrated an
example with a proportional hazards assumption between S and CDx and a gamma
frailty model between CDx and SDx. As the model is generally specified, independent
specification of these baseline hazards and more complex frailty model with larger
frailty effect can be adapted into the data analysis, given sufficient identifiability of
model parameters.
Given the basis work in Chapter II, we extended the joint model with a mixture
of cancer screening schedules to the analysis of cancer screening trials data. The
extended model enables us to estimate ad-hoc screening intensity (contamination)
jointly with the disease natural history an perform hypotheses testing for the screening
patterns across trial until loss of follow up. In addition, we can obtain the diagnosis-
free survival functions by adapting the trial settings and mixture of screening patterns,
as well as the natural disease progression features. For model simplification, in this
chapter we have assumed the common baseline hazard between tumor onset S and
clinical diagnosis CDx, and conditional dependence between CDx and SDx given S.
The two assumptions may be released by specifying different baseline hazard and
introducing frailty term into the model.
To link the formulated incidence models to mortality models for evaluating screen-
ing effect on reducing the risk of cancer death, we used the term mean lead time as the
proxy of screening intensity. By fitting the prostate cancer specific survival models,
we found that screening can significantly reduce the risk of prostate cancer death. As
the lead time was predicted with the incidence models, its standard error can also be
estimated for statistical inference purpose. In addition, because of the dependency
between time to CDx and time to SDx, more distributional characteristics can be





Supplementary Materials for Chapter II
A.1 Derivation of Model Quantities
The p.d.f of tumor onset S is:




Generally, when the conditional hazard function for a survival time T is a stochastic
process λ(t), then the marginal survival function G(t) = E[e−
∫ t
0 λ(ξ)dξ]. Extending the
formulation of Rice and Tsodikov (2016) to time-dependent predictors, we obtain the











































We obtain the marginal survival function incorporating risks of screening and clin-
ical diagnosis as the expectation over the distribution of latent event time S, frailty


































































































Follow (Rice and Tsodikov, 2016), we impose a proportional hazards (PH) assumption
linking dH1 and dH0 into a common dH. Given the maximum follow-up time υ,
differentiating the log-likelihood (2.10) we arrive at the following score equations for































































1− ∫ υτ ∑j∈R(t|x) ΨdH(τ)(t|Z̄txj)Ψ(t|Z̄txj) dM(t|Z̄txj)∑




























(1 + φ)(1 + φΛ̃s,t)
− 1
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1− ∫ υτ ∑j∈R(t|x) ΨdHscr(τ |x)(t|Z̄txj)Ψ(t|Z̄txj) dM(t|Z̄txj)∑



























































A.3 Asymptotics Properties of NPMLE Estimators
A.3.1 Martingale properties
We write the score functions for Ω = (β, {dH}, {dHscr}) as martingales (at the






. For simplicity, let
dΛi(t) = dΛ(t|Z̄txi), dNi(t) = dN(t|Z̄txi), dMi(t) = dM(t|Z̄txi),Ψi(t) = Ψ(t|Z̄txi).






































































Properties of martingale transform. (A.8) and (A.9) are martingales as εi(u, t,H;β)dMi(u)














































Therefore, the score functions Uβ, UH(t) and UHscr(t|x) are martingales at the true
model.
A.3.2 Consistency
We now present the consistency and weak convergence results for the proposed
NPMLE estimators Ω̂ = (β̂, Ĥ(t), Ĥscr(t|x)), mainly adapted from Hu and Tsodikov
(2014b). Let ‖·‖l∞[0,υ] denote the supremum norm in [0, υ] and ‖ω‖V [0,υ] the total
variation of ω(t) in [0, υ]. Define Q = {ω(t) : ‖ω‖V [0,υ] < ∞} such that Ĥ(t) and
Ĥscr(t|x) may be regarded as a bounded linear functional in l∞[Q], and ∆Ω̂0 =
{β̂ − β0, dĤ(t) − dH0(t), dĤscr(t|x) − dH0scr(t|x)} a random element in the metric
space Sp × l∞[Q], where p is the dimension of β0. We denote H as the compact
convex set in the metric space Sp × l∞[Q] in which Ω0 is contained.
Proof. To establish the consistency result from Proposition II.1: ‖Ĥ(·)−H0(·)‖l∞[0,υ]
p→
0, ‖Ĥscr(·|x)−H0scr(·|x)‖l∞[0,υ]
p→ 0 and ‖β̂ − β0‖ p→ 0, the following conditions are
verified:
1. Identifiability condition: The model is identifiable so that Λ = Λ0 uniformly
over Ω implies Ω = Ω0, which will ensure that for any sequence Ωn ∈ H, the
compact convex set in the metric space Sp × l∞[Q], lim infn→∞ `(Ωn) ≥ `(Ω0)
implies ‖Ωn − Ω0‖
p→ 0.






With these two conditions, since `n(Ω̂) = supΩ∈H`n(Ω)+op(1), then based on Theorem
2.12 in Kosorok (2008), we have ‖Ω̂− Ω0‖ p→ 0. We use three steps to verify these
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two conditions.
Step 1 Convexity and unique maximum of the likelihood function `.




η(t) · dH(t) + dHscr(t|x)
]
,
which are all functionals that depend on the processes H(·) and H(·|x) on [0, t]. Let
F (t) be the cumulative incidence function , R(t) be the survival function respectively.





where R0 and F 0 denote the corresponding true quantities respectively and the ex-
pectation is taken with respect to the covariate process Ztx.
Consider the negative true Kullback-Leibler distance,














consider a non-positive concave function f(t) = log t − t + 1, t = 1 is the unique
maximizer and f(1) = 0. Therefore, D has a uniformly unique maximum when
dΛ(t|x) = dΛ0(t|x).
Step 2 Identifiability conditions.
Since Λ is assumed to be a differentiable functional of H and Hscr, so is the likelihood
function `(Ω). Step 1 suggests that Ω0 = argmaxΩ∈H`(Ω) is unique, and `(Ω,Ω
0) is
identifiable so that Λ = Λ0 uniformly over Ω implies Ω = Ω0. Therefore, based on
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Lemma 14.3 of Kosorok (2008), we have lim infn→∞ `(Ωn) ≥ `(Ω0), thus the identifi-
ability condition is satisfied.
Step 3 Uniform convergence condition.
Assume that Ω is in the class of functions of bounded variation with integrable en-
velope, which implies that H and Hscr are bounded. Therefore, H belongs to a
Glivenko-Cantelli class, whose ε-entropy with bracketing number is bounded by A/ε,
where A is some constant. By the assumption of continuity of the functionals Λ
and `(Ω), and the integrability of the envelope of Ω, the integrand in `(Ω) is also
Glivenko-Cantelli. Therefore, we apply the uniform law of large numbers for the














log(η(t)dH(t) + dHscr(t|x)) + log Ψ(H(t), Hscr(t|x);β)
]
dNi(t)



















Consider a linear functional
n1/2
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where a is a real vector and b(t), e(t|x) are functions with bounded total variation.
Let B denote the vector consisting of the values of b(t) evaluated at the observed
failure times corresponding to the set {dH}, let E denote the vector consisting of
the values of e(t|x) evaluated at the observed failure times corresponding to the set
{dHscr} for cohort x; let E ′ = (a′,B′,E′). We have Proposition II.2.
Proof. Our proof closely follows that of Hu and Tsodikov (2014a, Supplementary
Materials C) and Rice and Tsodikov (2016, Supplementary Materials E). Denote the




, and the proposed NPMLE Ω̂ be the solution





where ` is defined in equation (2.10) and the estimate of H,Hscr are obtained using
the iterative reweighted algorithm of Chen (2009). Asymptotically, this is equivalent
to solving the marginal score directly.
Based on the martingale representation of U(Ω0) where Ω0 is the set of true param-
eters, and the fact that Ni(t), i = 1, ..., n are orthogonal, it follows by the martingale





where Uβ is a mean-zero p-variate normal random variable and UH(t), UHscr(t|x) are
mean-zero Gaussian processes. The variance-covariance function of U(t) can be char-
acterized by covariance functions σ2Hscr(s, t;β
0, H0, H0scr), σ
2
H(s, t;β





0, H0, H0scr), σ
2
H,β(t;β

















































which converges weakly as n→∞ to a mean-zero Gaussian process with covariance
function
σ2H(s, t;β





ε(u, s,H;β)ε(u, t,H;β)P (T ≥ u)Ψ (u) [η(u)dH(u)+dHscr(u|x)],
for s, t ∈ [0, υ]. Similarly, n−1/2UHscr(t|x), n−1/2Uβ are martingales converging to the
mean-zero Gaussian processes with covariance functions
σ2Hscr(s, t;β
0, H0, H0scr) =
∫ υ
0









P (X ≥ u) [η(u)dH(u) + dHscr(u|x)].
In addition,n−1/2UHscr(t|x),H(s), n−1/2UHscr(t|x),β and n−1/2UH(t),β are martingales that
converge to mean-zero Gaussian processes with covariance functions
σ2Hscr,H(s, t;β
0, H0, H0scr) =
∫ υ
0
ε(u, s,H;β)ε(u, t,Hscr;β)P (T ≥ u)Ψ (u) [η(u)dH(u)+dHscr(u|x)],
σ2Hscr,β(t;β
0, H0, H0scr) =
∫ υ
0








ε(u, t,H;β)Ψβ(u)P (T ≥ u) [η(u)dH(u) + dHscr(u|x)].
Let the limit in probability of the likelihood function (2.10) normalized as `/n, be





































. The operator I∞ acts on an arbitrary vector


















































= U(t) + op(1). (A.12)
Assuming that the Fredholm operator expressed by the kernel I∞ of the Fredholm
integral equation (A.12) of the first kind is square integrable, and that the equation
I∞Ω = 0 has only the trivial solution Ω = 0, then equation (A.12) has a unique
solution. By Theorem 3.3.1 of van der Vaart and Wellner (1996), there exists an





= I−10 (u, t)U(t) + op(1).
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= 0 with respect to Ω at the truth











































which represents the variance of the normalized score Gaussian process U(t). By the
functional delta method (Kosorok, 2008, Section 2.2.4), for a differentiable functional
F (Ω), n1/2
[
F (Ω̂)− F (Ω0)
]
converges weakly to a mean-zero Gaussian process with
variance-covariance function Ḟ (Ω0)′I−10 Ḟ (Ω0), where Ḟ (Ω) = ∂F∂Ω and the operator
products are defined similarly to (A.11). Applying this to (A.3.3) and replacing
operator products by matrix algebra, and I∞ by its consistent (matrix) estimator
n−1În, we obtain the weak convergence results.
A.4 Likelihood Hessian and the information matrix
Using direct algebraic manipulation, we have the following expression for the





















where Λ(t) is the subject-specific cumulative hazard, R(t|x) is the cohort x at risk
process, Ni(t) is the subject’s failure counting process, and dMi = dNi − dΛi is a
martingale increment under the true model for i ∈ R(t|x). We note that given t > s,
∂Λ(s)/∂dH(t) = 0, ∂Λ(s)/∂dHscr(t|x) = 0 so terms corresponding to dH(t) and
dHscr(t|x) functional component of Ω under the integral are zero until t. Therefore as
the martingale term turns into an op(1), and the first term into a consistent estimate
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Supplementary Materials for Chapter III
B.1 Derivations of Model Quantities
The conditional diagnosis-free survival functions for each mode (CDx and SDx):
GCDx(t|Z̄t, S) = e−
∫ t
0 I(ξ≥S)η(ξ)dH(ξ),
GSDx(t|Z̄t, S, N̄scr(t)) = exp
[∫ t
0
I(ξ ≥ S) log(1− α(ξ))dNscr(ξ)
]
.
The marginal diagnosis-free survival function for screening arm is:
Gscd (t|Z̄t) = E
[









= f(t, Iscr = 0|Z̄t) + f(t, Iscr = 1|Z̄t)
f(t, Iscr = 0|Z̄t) = ES,Nscr
{



























B.2 Derivation of Score Equations
The joint log-likelihood function for both control and screening arm is:






















Given the maximum follow-up time υ, differentiating the log-likelihood (3.12) we




























































































































































































































































































































I(τ < Aei)α + I(τ > Axi)r2α
]
∗
















































I(τ < Aei)α + I(τ > Axi)r2α
]
wscdHscr(τ).
































































































null predicted survival, control arm, PLCO
null predicted survival, screening arm, PLCO
observed survival, control arm, PLCO
observed survival, screening arm, PLCO
predicted survival, control arm, PLCO
predicted survival, screening arm, PLCO
KM curves for predicted and observed survival by age, PLCO
Figure B.1: Kaplan-Meier curves for predicted and observed survival from diagnosis by age for


















null predicted survival, screening arm, SEER
observed survival, control arm, SEER
observed survival, screening arm, SEER
predicted survival, control arm, SEER
predicted survival, screening arm, SEER
KM curves for predicted and observed survival by age, SEER
Figure B.2: Kaplan-Meier curves for predicted and observed survival from diagnosis by age for
control arm and screening arm, SEER.
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APPENDIX C
Supplementary Materials for Chapter IV
C.1 The mean lead time and empirical estimation
Lead time is usually defined as the amount of time by which clinical diagnosis
(i.e., diagnosis without screening) is advanced by screening. This version of lead time
is only defined in patients who are detected by screening and who, in the absence
of screening, would be clinically diagnosed. This definition excludes overdiagnosed
patients (i.e., patients detected by screening who would not be clinically diagnosed
in the absence of screening), patients clinically diagnosed, and patients without any
diagnosis. Our goal here, however, is to derive a generic surrogate of the intensity of
screening and diagnosis in a given population that is amenable to empirical (model-
free, robust) estimation and prediction. Nevertheless, due to its close theoretical
relationship with the mean lead time (described below), we adopt this terminology.
In a screening trial, the time from randomization to screen detection (TSDx) and
the time from randomization to clinical diagnosis (TCDx) are competing risks that are
never both observed for the same patient. Consequently, their full joint distribution
is non-identifiable without specific modeling assumptions (Tsiatis, 1975). However,
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the mean lead time (i.e., the mean time difference TCDx − TSDx , which is non-zero
only if TSDx < TCDx) is identifiable and can be calculated empirically. Formally, the
mean lead time is equal to the difference between the mean time to diagnosis without
screening minus the mean time to diagnosis with screening:
E
(






The two terms on right-hand side can be estimated empirically as the areas under
the survival curves for diagnosis in the absence and in the presence of screening.
Further, this empirical approach for estimating the mean lead time extends to a trial
with finite follow-up (Tmax). Specifically, the time of screen detection becomes T
′
SDx =
min(Tmax, TSDx), the time of clinical diagnosis becomes T
′
CDx = min(Tmax, TCDx) , and
the mean times from randomization to diagnosis in the absence and in the presence
of screening can be estimated as the areas under the survival curves for diagnosis
up to the landmark Tmax (Appendix Figure C.1). Restricted survival times have
been used in medical statistics and this time-restricted version of the mean lead time
corresponds exactly to the so-called restricted mean survival time (Uno et al., 2014)
when the survival event of interest is cancer diagnosis.
Note that the mean lead time estimated in this way is not interpretable as the mean
lead time for non-overdiagnosed screen-detected cases who would have been clinically
diagnosed in the absence of screening (within the follow-up of the trial). Rather,
this version of the mean lead time is a population-level measure for all participants
in the trial arm, and greater magnitudes can indicate both greater numbers of non-
overdiagnosed cases detected early as well as greater numbers of overdiagnosed cases.
Because this version of the mean lead time is positively related to the number of
non-overdiagnosed cases, it is an acceptable surrogate for the intensity of screening
and diagnostic workup for our analyses. After all, if greater magnitudes were only
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Figure C.1: (A) Mean time from randomization to diagnosis without screening, (B) mean time from
randomization to diagnosis with screening, and (C) mean lead time, each restricted to 11 years of
follow-up, correspond to areas under the associated diagnosis-free survival curves or to the difference
between these areas.
attributable to greater numbers of overdiagnosed cases, there would be no observed
prostate cancer mortality reduction that could be associated with this measure.
Finally, to standardize the measure across trial arms in this study, we scaled each
estimated MLT by a common baseline probability of (screen or clinical) diagnosis
during follow-up, 1/Pr(diagnosis in [0, Tmax]), making the MLT a conditional average
given any mode of prostate cancer diagnosis during the trial.
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C.2 Descriptions of three prostate cancer natural history
models, adaptations to trial settings, and estimation
methods
Three models of prostate cancer development, progression, and detection were
used to estimate MLTs associated with prostate-specific antigen (PSA) screening
in each arm of the European Randomized Study of Screening for Prostate Cancer
(ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screen-
ing trial. Two of the models are microsimulation models that generate individual
life histories comprised of cancer natural history and diagnosis; the third is an ana-
lytic mathematical model that represents corresponding events in an integrated set
of analytic probability models. The models previously estimated age-specific risks of
onset of latent cancer, transitions through histologic stages and grades, and clinical
diagnosis in the absence of screening (Appendix Figure C.2) in the general US popu-
lation (https://resources.cisnet.cancer.gov/registry/site-summary/prostate). For this
study, the models were adapted using data on screening and biopsy behavior before
and after the start of each trial and prostate cancer incidence data during the trials,
including age, stage, and grade at diagnosis and mode of detection. Details for each
model are given below. The adapted models closely reproduced incidence patterns
observed in intervention and control arms of both trials. These incidence patterns ob-
tained from the models were then used in place of observed incidence data to estimate
the MLT in each trial arm using the empirical approach described above.
In the intervention arms, the models implemented center-specific screening and
biopsy-referral protocols subject to observed adherence, which implied an average of
2.1-3.3 (ERSPC) or 6.9-7.5 (PLCO) tests per person during 11 years of follow-up
(ranges across models). In the PLCO control arm, the models assumed screening test
frequencies by age and birth year as previously reconstructed for the US population
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Figure C.2: Health states and modeled transitions between states in the FHCRC, MISCAN, and
UMICH models.
with increased tests during the intervention period as previously noted (Pinsky et al.,
2010; Gulati et al., 2012), which implied an average of 3.8-5.1 tests per person. In the
ERSPC control arm, the models assumed screening occurred at 5% of the frequency
of PSA screening in the US population over the same calendar period as the trial,
which implied an average of 0.2-0.4 tests per person.
C.2.1 The Fred Hutchinson Cancer Research Center (FHCRC) model
The FHCRC model consists of two connected pieces: PSA growth and disease
progression. PSA growth is linear on the log scale, with a larger slope after dis-
ease onset. PSA growth rates were estimated using serial screening results from the
placebo arm of the Prostate Cancer Prevention Trial (Thompson et al., 2003). Dis-
ease progression encompasses tumor onset, metastatic spread, and clinical diagnosis
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that would occur in the absence of screening. The risk of onset increases with age
and risks of progression to subsequent events increase with PSA levels. All cancers
are T-stage ≤ T2a at onset and can progress to T-stage > T2a and to T4 or M1.
Cancer grade (Gleason score 2-6, 7, or 8-10) is fixed at onset. To estimate progression
risk parameters for the US population, we superimposed PSA screening and biopsy
frequencies using published patterns and determined the parameter values (using sim-
ulated maximum likelihood) so that model incidence closely matched incidence in the
Surveillance, Epidemiology, and End Results (SEER) program by age, year, stage,
and grade (Gulati et al., 2010).
To adapt the model to the PLCO, we assumed eligible men underwent PSA screen-
ing based on our reconstruction for general US population, ensured all men were un-
diagnosed at entry into the trial, and specified enrollment, attendance, and follow-up
patterns to match observed data for all men ages 55-74 years at enrollment. Men ran-
domized to the intervention arm underwent 6 years of annual DRE and PSA screening,
while men randomized to the control arm underwent more intensive screening than
in the general population (Pinsky et al., 2010). Men in either arm with suspicious
DRE or PSA>4.0 ng/mL received biopsies based on observed frequencies in the in-
tervention arm by age and PSA level, and we assumed the sensitivity of a biopsy to
detect latent cancer improved from 80% in 1993 to 93% in 2000 and later (Gulati et al.,
2010). After the trials 6-year intervention period, men were randomized to either arm
resumed screening according to population screening patterns. Model assumptions
of non-compliance and contamination were previously described (Gulati et al., 2012).
While the model for the general US population projected incidence that matched ob-
served incidence reasonably well without adjustment, we re-estimated risks of onset
and of progression to produce modestly improved fit. The modest changes are con-
sistent with a cohort enriched for healthy behavior and higher socioeconomic status
(Pinsky et al., 2010).
88
Adaptation to the ERSPC core age group (ages 55-69 years at enrollment) was
similar except that enrollment, attendance, follow-up, DRE and PSA screening, PSA
threshold for biopsy, and receipt of biopsy were modeled for each center individually
to reflect heterogeneity in recruitment and protocols. We assumed the control arm un-
derwent less intensive screening than the US population (receiving 5% of screens), con-
sistent with contamination reported for several centers (Ciatto et al., 2003; Bokhorst
et al., 2014). As for the PLCO, while the model projected incidence that matched
observed incidence reasonably well without adjustment, we re-estimated risks of on-
set and of progression to produce modestly improved fit. In particular, allowing for
differential risks of clinical presentation for each stage and grade, the model achieved
a noticeably improved fit for metastatic incidence.
C.2.2 The Erasmus University Medical Center MIcrosimulation SCreen-
ing ANalysis (MISCAN) model
The MISCAN model is also a microsimulation model of individual life histories.
The risk of onset increases with age, and risks of cancer progression are modeled as
a semi-Markov process over a sequence of tumor states. There are 18 preclinical de-
tectable states determined by combinations of histologic grade (SEER categories well,
moderately, and poorly differentiated), clinical T-stages (American Joint Committee
on Cancer stages T1, T2, and T3), and clinical M-stages (M0 and M1). Risks of stage
and grade progression are both modeled and allowed to vary across combinations and
from a preclinical to clinical state. The chance of a screen protocol detecting a pre-
clinical tumor depends on screening frequency, attendance rates, the PSA threshold
for a positive test, and, after a positive PSA test, biopsy compliance and sensitivity.
Baseline model parameters were originally estimated using data from the Rotter-
dam section of the ERSPC (Draisma et al., 2003). For adaptation to the US popula-
tion, we re-estimated the PSA test sensitivity parameters and a modified stage-specific
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risk of clinical diagnosis to capture different pre-PSA disease diagnosis patterns. US-
specific estimates for the parameters were obtained by calibrating the model to the
observed age-specific incidence and age-specific SEER stage distribution using maxi-
mum likelihood (Wenver et al., 2010).
Adaptations of the US model to the PLCO and of the Rotterdam model to the
ERSPC were similar to those for the FHCRC model. Specifically, after accounting
for differences in settings and protocols, we re-estimated model parameters in each
trial arm to match observed incidence by age and year, and the associated stage
distribution, by minimizing a sum of the chi-square errors. The minimization was
achieved using an adapted version of the Nelder-Mead simplex algorithm. The algo-
rithm was initially run using small sample sizes (i.e., 20,000 men) then repeated with
larger sample sizes (i.e., 2,000,000 men) when the initial optimization step could not
be further improved. For this analysis, we first re-estimated the disease progression
rates and the PSA test sensitivity relative to stage- and grade-specific incidence of
clinical cancers in the control arms and then relative to screen-detected and interval
cancers in the intervention arms.
C.2.3 The University of Michigan (UMICH) model
The model is similar with the models in Chapter 2 and Chapter 3, which is an an-
alytic model comprised of three components. A marginal incidence model (Tsodikov
et al., 2006) is a two-stage model for a given individual screening schedule (a point
process A). The first stage is defined by the hazard of the first PSA test for a man at
a given age and calendar time. A second hazard is defined for men who already had
their first PSA test. Both hazards of PSA testing rely on a retrospective analysis of
PSA testing. Cancer diagnosis is defined as a result of two competing risks, clinical
diagnosis (CDx) and diagnosis due to screening (SDx), whichever comes first. The
risks are dependent based on a common natural history of the disease, with both risks
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equal to zero until the onset of a detectable tumor. Estimation is based on parametric
maximum likelihood, which averages over the unobserved screening schedule and nat-
ural history processes. Once the stochastic process mixed model is fit, predictions for
lead time, overdiagnosis, age of tumor onset, and other characteristics in the patient
and the population are predicted using Bayesian conditional probabilities.
Cancer stage and grade are represented as a categorical mark (Z) on the incident
cancer. We use a mixed multinomial model to specify the distribution of stage and
grade at diagnosis, where the mixing variables represent key unobserved features of
latent disease progression (e.g., age at onset), predicted as conditional distributions,
given results of the marginal incidence model. Stage and grade are modeled using
a mixed multinomial model. The model is estimated by maximum likelihood. We
developed a special method of artificial mixtures and the quasi-EM algorithm to deal
with the curse of dimensionality in complex models (Tsodikov et al., 2014). Appli-
cations of the multinomial model and the stage- and grade-specific incidence model
have been previously described (Tsodikov and Chefo, 2008; Chefo and Tsodikov, 2009;
Wang and Tsodikov, 2010). Given age, year, stage, and grade at diagnosis, the model
projects unobserved characteristics of disease natural history and clinical diagnosis in
the absence of screening.
Finally, disease progression is modeled as a stochastic process Z(ξ) as a function
of time ξ measured from the point of onset. Given the two potential competing risks
of clinical and screening diagnosis, we can define the corresponding potential values
of the cancer development process Z(ξSDx) and Z(ξCDx) for the same individual. Let
ISDx be 1 for screening and 0 for clinical diagnosis and define the vector V = (a, z)
combine age, stage, and grade at diagnosis. The disease progression model defines
the probability of disease progression between these two potential points of diagnosis
by the transition model [V0|V1]. For a screen-detected patient, let fV (V0|V1, x) be
the joint pdf of disease presentation at CDx (with characteristics V0) given observed
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characteristics V1 at SDx and birth cohort x. The transition probabilities between
the two points of diagnosis (SDx, CDx) are modeled as functions of the lead time
ξL, pb(z0|z1, ξL), summarized as a progression probability matrix (PPM). Under the
null hypothesis of no screening benefit, the baseline PPM probabilities pb are not
affected by intervention applied at the point of SDx. Thus, we consider two model
predictions for cancer incidence: (1) λI(a, z|S̄) under no screening and (2)λI(a, z|IS)
under ignored screening (no effect of early detection). The first scenario does not
involve the PPM, while the second scenario uses PPM. Making the two counterfac-
tual incidence predictions as close as possible using a Poisson-type distance measure
provides a robust estimating procedure.
To estimate mean lead times in this study, only the marginal incidence model
needed to be estimated. Because screening intensities for the trial populations are
only partially known, the competing risk of screen diagnosis during the follow-up
period was estimated nonparametrically and jointly with the parametric natural his-
tory model as a matrix by age and follow-up time using maximum likelihood. Thus,
in contrast to the MISCAN and FHCRC microsimulation models, which combined
empirical data with trial protocols, the UMICH model directly incorporated empiri-
cal patterns of enrollment, attendance, and follow-up; PSA screening and receipt of
biopsy; and age, year, stage, grade, and mode of detection for incident cancers into
the aggregate data-driven nonparametric risk of screening diagnosis and paramet-
ric risk of clinical diagnosis. The resulting version of the marginal incidence model
was used to generate the expected incidence in each trial arm. Lead times in each
trial arm were predicted using the method similar to the empirical approach, except
that the model-based incidence predictions in each trial arm were used instead of
the empirical time to diagnosis survival curves. Comparable assumptions were made
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